var title_f19_50_20256="2-hand chest method PI";
var content_f19_50_20256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Child CPR: 2-handed chest compressions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 305px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pressing on the chest for CPR is called doing \"compressions.\" To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim, stack your hands on top of one another with both palms facing down, and lock your fingers together. Holding your arms straight, press on the center of the victim's chest with the heel of your bottom hand. Use your body weight, rather than the strength of your arms, to press on the chest. Make sure the victim's chest drops down at least 2 inches (5 centimeters) under your weight with each push. Between compressions, lift all pressure off the victim's chest so that his or her chest goes back to where it was.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20256=[""].join("\n");
var outline_f19_50_20256=null;
var title_f19_50_20257="Diastasis symphysis pubis";
var content_f19_50_20257=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diastasis of the symphysis pubis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 548px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Preoperative radiograph of the pelvis in a child with classic bladder exstrophy. Note the diastasis of the symphysis pubis and the inability to view the obturator foramina (Top). Post-operative radiograph, after pelvic osteotomy, shows nice approximation of the symphysis pubis and a clear view of the obturator foramina (Bottom).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Gearhart, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20257=[""].join("\n");
var outline_f19_50_20257=null;
var title_f19_50_20258="Patient information: Achalasia (The Basics)";
var content_f19_50_20258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16153\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"         Upper digestive tract",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/40/643\">",
"          Barium swallow showing achalasia",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"           Upper endoscopy",
"          </a>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?24/2/24610\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?32/41/33426\">",
"         Patient information: Upper endoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/55/2934\">",
"         Patient information: Achalasia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/30/38373\">",
"         Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/0/21506\">",
"         Patient information: Upper endoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Achalasia (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/achalasia-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11258717\">",
"      <span class=\"h1\">",
"       What is achalasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Achalasia is a condition that affects the esophagus. The esophagus is the tube that moves food from the mouth to the stomach (",
"      <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"       figure 1",
"      </a>",
"      ). At the lower end of the esophagus, where it connects to the stomach, there is a muscle called the lower esophageal sphincter (LES). When the LES tightens, food can&rsquo;t move from the esophagus into the stomach. When the LES relaxes, food can move from the esophagus into the stomach.",
"     </p>",
"     <p>",
"      When people have achalasia:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The lower part of the esophagus does not work normally",
"       </li>",
"       <li>",
"        The LES doesn&rsquo;t relax, so food can&rsquo;t move into the stomach",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11258724\">",
"      <span class=\"h1\">",
"       What are the symptoms of achalasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The most common symptom of achalasia is trouble swallowing foods and drinks. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Chest pain",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Heartburn",
"       </li>",
"       <li>",
"        Feeling like you have a lump in your throat",
"       </li>",
"       <li>",
"        Losing weight without trying",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11258731\">",
"      <span class=\"h1\">",
"       Is there a test for achalasia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects that you have achalasia, he or she will do 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Chest X-ray",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?18/37/19028?source=see_link\">",
"         Barium",
"        </a>",
"        swallow &mdash; Your doctor will give you a drink called &ldquo;barium.&rdquo; Then he or she will take an X-ray as the barium moves down your esophagus (",
"        <a class=\"graphic graphic_figure graphicRef69107 \" href=\"UTD.htm?0/40/643\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Measuring the pressure in your esophagus and LES &mdash; Your doctor will put a thin tube into your mouth or nose and down into the esophagus. The tube will measure the pressure there. This test can tell your doctor for sure if you have achalasia.",
"       </li>",
"       <li>",
"        A procedure called an upper endoscopy &mdash; Your doctor will put a thin tube with a camera on the end into your mouth and down into your esophagus and stomach (",
"        <a class=\"graphic graphic_figure graphicRef75392 \" href=\"UTD.htm?36/39/37490\">",
"         figure 3",
"        </a>",
"        ). He or she will look at the lining of the esophagus and stomach. He or she might also take a small sample of tissue from the lining and look at the sample under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11258738\">",
"      <span class=\"h1\">",
"       How is achalasia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors can treat achalasia in different ways. Treatments cannot cure achalasia, but they can improve symptoms. The different treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicines &mdash; Different medicines can relax the LES. People can take these medicines before they eat.",
"       </li>",
"       <li>",
"        A shot of medicine into the LES &mdash; During an upper endoscopy, a doctor can give a shot of medicine into the LES to make it relax.",
"       </li>",
"       <li>",
"        Making the LES wider &mdash; During an upper endoscopy, a doctor can put a thin wire into a person&rsquo;s mouth and down into the esophagus. He or she sends a deflated balloon over the wire until the balloon reaches the LES. He or she puts air into the balloon to widen the LES. Then he or she lets the air out of the balloon and removes it and the wire.",
"       </li>",
"       <li>",
"        Surgery &mdash; A doctor can cut open the LES to make it wider.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11258745\">",
"      <span class=\"h1\">",
"       Which treatment is right for me?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To choose the treatment that&rsquo;s right for you, talk with your doctor. Ask him or her about the benefits, risks, and side effects of each treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11258752\">",
"      <span class=\"h1\">",
"       Do I need to follow up with my doctor?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You will need to follow up with your doctor on a regular basis. He or she will check that your treatment is working and that it isn&rsquo;t causing side effects.",
"     </p>",
"     <p>",
"      Your doctor will also keep checking you for long-term problems. That&rsquo;s because people with achalasia have a higher than normal chance of getting cancer or other problems of the esophagus.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11258889\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=see_link\">",
"       Patient information: Upper endoscopy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/55/2934?source=see_link\">",
"       Patient information: Achalasia (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"       Patient information: Upper endoscopy (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"       Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?19/50/20258?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16153 Version 4.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20258=[""].join("\n");
var outline_f19_50_20258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258717\">",
"      What is achalasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258724\">",
"      What are the symptoms of achalasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258731\">",
"      Is there a test for achalasia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258738\">",
"      How is achalasia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258745\">",
"      Which treatment is right for me?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258752\">",
"      Do I need to follow up with my doctor?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11258889\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16153\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\">",
"      Upper digestive tract",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/40/643\">",
"       Barium swallow showing achalasia",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37490\">",
"        Upper endoscopy",
"       </a>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/55/2934?source=related_link\">",
"      Patient information: Achalasia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=related_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/41/33426?source=related_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_50_20259="Glomerular structure";
var content_f19_50_20259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    The glomerular filtration barrier",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 242px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Blood enters the glomerular capillaries and is filtered across the endothelium and the glomerular basement membrane and through the filtration slits between podocyte foot processes to produce the primary urine filtrate. In healthy glomeruli, this barrier restricts the passage of macromolecules. CatL, the expression of which is increased in human proteinuric diseases and in an LPS-induced mouse model of proteinuria, causes proteinuria and foot process effacement through cleavage of the GTPase dynamin, an actin-binding protein. The same effects are induced by gene delivery into mice of dynK44A - a mutant form of dynamin that does not bind GTP&nbsp;- or of the CatL-cleaved product of dynamin (p40). Conversely, gene delivery into proteinuric mice of dynL356Q and dynR725A, two CatL-resistant dynamin mutants, reverses proteinuria and foot process effacement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ronco P. Proteinuria: is it all in the foot?. J Clin Invest 2007; 117:2079. Copyright &copy;2007 American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20259=[""].join("\n");
var outline_f19_50_20259=null;
var title_f19_50_20260="Tiopronin: Patient drug information";
var content_f19_50_20260=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tiopronin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"     see \"Tiopronin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F228218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thiola&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop kidney stones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tiopronin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If this drug has caused anemia, low platelet count, or low white blood cell count before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12137 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-197.136.42.3-D0BB386C34-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20260=[""].join("\n");
var outline_f19_50_20260=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F228218\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012474\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012473\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012478\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012479\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012481\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012476\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012477\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012482\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012483\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=related_link\">",
"      Tiopronin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_50_20261="Effect of antihypertensive treatment on renal function in essential hypertension";
var content_f19_50_20261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effect of antihypertensive treatment on renal function in essential hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20261/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20261/contributors\">",
"     Johannes FE Mann, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20261/contributors\">",
"     Karl F Hilgers, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20261/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20261/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20261/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20261/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20261/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/50/20261/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal function may deteriorate because of uncontrolled hypertension. Even minimal elevations in blood pressure (BP), still below the",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg level used to define hypertension, are associated with increased renal arteriosclerosis in autopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/1\">",
"     1",
"    </a>",
"    ]. Since adequate control of hypertension slows the rate of renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/2\">",
"     2",
"    </a>",
"    ], the effects of antihypertensive therapy on renal function need to be carefully considered.",
"   </p>",
"   <p>",
"    Antihypertensive therapy has both acute and chronic effects on renal function in patients with essential primary hypertension. In early disease, for example, renal function is usually normal; in this setting, lowering the BP induces little change in glomerular filtration rate (GFR) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/3\">",
"     3",
"    </a>",
"    ]. In comparison, some patients have early renal vasoconstriction leading to a fall in GFR below 80",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Reversal of the vasoconstriction with an angiotensin-converting enzyme (ACE) inhibitor or calcium channel blocker can raise the GFR by 20 to 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"     \"Renal effects of ACE inhibitors in hypertension\"",
"    </a>",
"    .) Blacks may have an initial decrease in GFR compared with an increase in whites [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHRONIC EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with prolonged uncontrolled hypertension are at increased risk of developing chronic renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/6\">",
"     6",
"    </a>",
"    ]. The risk of this complication is much greater in blacks and in patients with moderate and severe hypertension (",
"    <a class=\"graphic graphic_figure graphicRef62524 \" href=\"UTD.htm?31/16/32013\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11174?source=see_link\">",
"     \"Hypertensive complications in blacks\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It must be emphasized, however, that the percentage of patients with mild hypertension who develop end-stage renal disease (ESRD) is relatively small, being less than 1 percent after 16 years in the MRFIT trial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis\", section on 'Incidence of renal failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prolonged blood pressure (BP) control will usually minimize the degree of renal damage, leading to a stable plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/2\">",
"     2",
"    </a>",
"    ]. There are, however, patients in whom proteinuria develops or the plasma creatinine concentration continues to rise slowly over a period of years despite seemingly adequate antihypertensive therapy. This is most likely to occur in blacks, in patients who have underlying chronic kidney disease (CKD) or a family history of ESRD, and in patients with vascular disease as manifested by older age, higher baseline BP, and hyperuricemia.",
"   </p>",
"   <p>",
"    Hyperuricemia (independent of diuretic therapy) has been attributed to a reduction in renal blood flow induced by the arterial and arteriolar disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/7\">",
"     7",
"    </a>",
"    ]. However, some have proposed that it may have a key causal role in the onset of essential hypertension, with increased uric acid levels resulting in endothelial dysfunction, vasculopathy, and elevated BP [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/8\">",
"     8",
"    </a>",
"    ]. Nevertheless, there is so far little evidence that treatment of hyperuricemia has a role in the treatment of hypertension.",
"   </p>",
"   <p>",
"    Why renal damage may progress despite seemingly adequate control of the hypertension is uncertain. It is possible that some of these patients have a different renal disease that is worsened by hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .) Among blacks, the increased risk for progression of renal disease is likely related to a genetic defect with less contribution from hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H9804961#H9804961\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'FSGS in African Americans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, aiming for a BP of",
"    <span class=\"nowrap\">",
"     140/85",
"    </span>",
"    to 90 mmHg may be inadequate to prevent renal damage in susceptible subjects. It is possible that maintaining a diastolic pressure of 80 mmHg or less would be more beneficial in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=see_link\">",
"     \"What is goal blood pressure in the treatment of hypertension?\"",
"    </a>",
"    .) The suggestion from a large epidemiologic study that higher BP",
"    <strong>",
"     within the normal range",
"    </strong>",
"    may be associated with renal injury over a period of many years is compatible with the hypothesis that more aggressive BP control may be beneficial in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/10\">",
"     10",
"    </a>",
"    ]. Moreover, based upon the findings of the Third National Health and Nutrition Examination Survey of a representative sample of the United States population, an estimated 5.6 million people have an elevated serum creatinine that is strongly related to inadequate treatment of hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative explanation for progressive disease is persistent intraglomerular hypertension despite adequate control of the systemic BP. It may be important in this regard that, at least in animal models, angiotensin-converting enzyme (ACE) inhibitors lower the intraglomerular pressure by preferentially decreasing the resistance at the efferent (postcapillary) glomerular arteriole [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/12\">",
"     12",
"    </a>",
"    ]. ACE inhibitors have been found to slow the progression of diabetic and nondiabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some studies, other drugs that presumably lack this preferential effect on efferent arteriolar resistance have also been found to slow the rate of renal damage, similar to ACE inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/14\">",
"     14",
"    </a>",
"    ]. However, most studies support the notion that ACE inhibitors are more effective in this regard in many forms of kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/2\">",
"     2",
"    </a>",
"    ]. It is difficult to assess the relative importance of the specific type of drug versus the effective reduction of BP or the relief of other major risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/2,15\">",
"     2,15",
"    </a>",
"    ]. However, these considerations are based upon studies performed in patients with kidney disease, and their importance for patients with essential hypertension is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the long-term renal benefit of antihypertensive therapy in most patients, the initial reduction in blood pressure (BP) may be associated with a transient elevation in the plasma creatinine concentration and a fall in the glomerular filtration rate (GFR). This effect is most likely to occur with moderate to severe hypertension. The development of renal failure is usually associated with one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A relatively marked and rapid reduction in BP, often exceeding 25 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/17\">",
"       17",
"      </a>",
"      ], although any antihypertensive drug can diminish renal function if the vascular disease is diffuse and severe. In the presence of a drug-induced fall in renal perfusion pressure, angiotensin II participates in the autoregulatory response that attempts to maintain the GFR; this contribution is blocked by an ACE inhibitor or ARB. The development of renal failure is most common in bilateral renal artery stenosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=see_link\">",
"       \"Renal effects of ACE inhibitors in hypertension\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Concurrent volume depletion, most often due to diuretic therapy, which makes maintenance of the GFR more angiotensin II-dependent.",
"     </li>",
"     <li>",
"      Concurrent heart failure.",
"     </li>",
"     <li>",
"      The use of nonsteroidal antiinflammatory drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impairment in GFR following the institution of antihypertensive therapy is usually reversible. The proper approach varies with the clinical setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporarily discontinuing treatment is indicated in patients who have had an excessive reduction in BP. In this setting, therapy can usually be safely restarted at a lower dose. Particular caution is needed with ACE inhibitors and ARBs.",
"     </li>",
"     <li>",
"      Continuing antihypertensive therapy is reasonable as long as the rise in the plasma creatinine concentration is less than 30 percent of the pretreatment level. This is based upon the evidence that persistent BP control will lead to regression of arteriolar hyperplasia, and the plasma creatinine concentration will generally return to or occasionally fall below the pretreatment level over a period of weeks to months. In many studies, ACE inhibitors produced a transient initial rise in serum creatinine but a beneficial effect on renal function in the long term [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/18-20\">",
"       18-20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reversing volume depletion by discontinuing excessive diuretic therapy may be beneficial when an unacceptable decline in GFR follows the institution of an ACE inhibitor [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20261/abstract/17\">",
"       17",
"      </a>",
"      ]. If this is ineffective or the patient has not been taking a diuretic, then switching to a drug that does not reduce intraglomerular pressure (such as a calcium channel blocker) is indicated.",
"     </li>",
"     <li>",
"      Evaluation for unrecognized bilateral renal artery stenosis should be considered, particularly in older patients with extensive atherosclerosis elsewhere, or if renal function rapidly deteriorates soon after starting a renin suppressing drug. The selection of patients who should be screened for renal artery stenosis is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=see_link&amp;anchor=H3#H3\">",
"       \"Who should be evaluated for renovascular or other causes of secondary hypertension?\", section on 'Clinical clues for renovascular hypertension'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036798\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antihypertensive therapy has both acute and chronic effects on renal function in patients with essential primary hypertension. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prolonged blood pressure (BP) control will usually minimize the degree of renal damage, leading to a stable plasma creatinine concentration. However, proteinuria may develop, or the plasma creatinine concentration may continue to slowly rise in some patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Chronic effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite the long-term renal benefit of antihypertensive therapy, the initial reduction in BP may be associated with a transient elevation in the plasma creatinine concentration. The development of acute kidney injury (AKI) is usually associated with a relatively marked reduction in BP; the use of an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); concurrent volume depletion; and nonsteroidal antiinflammatory drugs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The impairment in glomerular filtration rate (GFR) following the institution of antihypertensive therapy is usually reversible. The proper approach to treatment varies with the clinical setting. A mild impairment (a rise in serum creatinine of less than 30 percent of the pretreatment level) does not require altering the antihypertensive therapy in most cases. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/1\">",
"      Ninomiya T, Kubo M, Doi Y, et al. Prehypertension increases the risk for renal arteriosclerosis in autopsies: the Hisayama Study. J Am Soc Nephrol 2007; 18:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/2\">",
"      Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/3\">",
"      Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure control and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis 1997; 29:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/4\">",
"      Morrone LF, Ramunni A, Fassianos E, et al. Nitrendipine and amlodipine mimic the acute effects of enalapril on renal haemodynamics and reduce glomerular hyperfiltration in patients with chronic kidney disease. J Hum Hypertens 2003; 17:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/5\">",
"      Mitchell HC, Smith RD, Cutler RE, et al. Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. Am J Kidney Dis 1997; 29:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/6\">",
"      Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/7\">",
"      Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/8\">",
"      Reynolds T. Serum uric acid, the endothelium and hypertension: an association revisited. J Hum Hypertens 2007; 21:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/9\">",
"      Lazarus JM, Bourgoignie JJ, Buckalew VM, et al. Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group. Hypertension 1997; 29:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/10\">",
"      Perneger TV, Nieto FJ, Whelton PK, et al. A prospective study of blood pressure and serum creatinine. Results from the 'Clue' Study and the ARIC Study. JAMA 1993; 269:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/11\">",
"      Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/12\">",
"      Maki DD, Ma JZ, Louis TA, Kasiske BL. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/13\">",
"      Mulrow CD, Townsend RR. Guiding lights for antihypertensive treatment in patients with nondiabetic chronic renal disease: proteinuria and blood pressure levels? Ann Intern Med 2003; 139:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/14\">",
"      Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/15\">",
"      Lo SH, Mo KL, Wong KS, et al. Aristolochic acid nephropathy complicating a patient with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2004; 19:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/16\">",
"      Weiner DE, Tighiouart H, Levey AS, et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007; 18:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/17\">",
"      Hricik DE. Captopril-induced renal insufficiency and the role of sodium balance. Ann Intern Med 1985; 103:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/18\">",
"      Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/19\">",
"      Hirsch S, Hirsch J, Bhatt U, Rovin BH. Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success. Am J Nephrol 2012; 36:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20261/abstract/20\">",
"      Ruggenenti P, Remuzzi G. Dealing with renin-angiotensin inhibitors, don't mind serum creatinine. Am J Nephrol 2012; 36:427.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3822 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-3636CB1C0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20261=[""].join("\n");
var outline_f19_50_20261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1036798\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHRONIC EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1036798\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3822|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/16/32013\" title=\"figure 1\">",
"      Blood pressure and kidney related mortality in blacks",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/42/6824?source=related_link\">",
"      Clinical features, diagnosis, and treatment of hypertensive nephrosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/58/11174?source=related_link\">",
"      Hypertensive complications in blacks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/60/19398?source=related_link\">",
"      Renal effects of ACE inhibitors in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/40/33417?source=related_link\">",
"      What is goal blood pressure in the treatment of hypertension?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/21/27991?source=related_link\">",
"      Who should be evaluated for renovascular or other causes of secondary hypertension?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_50_20262="Pregnancy and Marfan syndrome";
var content_f19_50_20262=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy and Marfan syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Michael J Wright, MBChB, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20262/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/50/20262/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Marfan syndrome (MFS, MIM #154700) is an autosomal dominant condition with a reported incidence of 1 in 3000 to 5000 individuals. There is a wide range of clinical severity associated with MFS. Although many clinicians view the disorder in terms of classic ocular, cardiovascular, and musculoskeletal abnormalities, these patients also demonstrate significant involvement of the lung, skin, and central nervous system.",
"   </p>",
"   <p>",
"    Pregnancy is a high-risk period for aortic dissection and rupture for women with MFS. The increased risk may be due to increased arterial wall stress associated with the hypervolemic and hyperdynamic circulatory state",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hormonal effects on aortic wall composition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of pregnancy in women with MFS and related disorders will be reviewed here. The genetics, pathogenesis, clinical manifestations, diagnosis, and management of MFS and related disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two issues must be addressed with respect to women with MFS who are considering pregnancy: assessment of the risk of aortic",
"    <span class=\"nowrap\">",
"     dissection/rupture;",
"    </span>",
"    and management during pregnancy, including issues related to delivery. Counseling regarding the risk of inheritance of this autosomal dominant condition is also indicated. The 50 percent chance of transmission from an affected mother to her child, phenotypic variability, and the availability of prenatal diagnostic testing should be discussed. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF RISK OF AORTIC DISSECTION/RUPTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with MFS with aortic root dilatation are at increased risk for aortic dissection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rupture, although a normal dimension does not exclude the possibility of dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. This risk and the potential alternatives (childlessness, adoption, and use of a gestational carrier or surrogate pregnancy) should be discussed with the patient.",
"   </p>",
"   <p>",
"    Any woman with MFS who is contemplating pregnancy should have a screening transthoracic echocardiogram for assessment of aortic root dimension, as well as consultation with a cardiologist, maternal-fetal medicine specialist, and geneticist in order to provide adequate data regarding risks of pregnancy to her and her offspring.",
"   </p>",
"   <p>",
"    The risk of aortic rupture or dissection during pregnancy is difficult to quantify, since limited data are available. Complications can occur at any time during pregnancy or postpartum, but are most often seen in the second and third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/2\">",
"     2",
"    </a>",
"    ]. There is general agreement that risk increases at larger aortic root diameters:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of dissection or other serious complications such as endocarditis or heart failure has been estimated to be approximately 1 percent in women with an aortic root diameter &le;40 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/3-6\">",
"       3-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both the 2006 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      guidelines on valvular heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/7\">",
"       7",
"      </a>",
"      ] and the 2003 European Society of Cardiology (ESC) task force [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/5\">",
"       5",
"      </a>",
"      ] concluded that an aortic root diameter &gt;40 mm in women with MFS identifies a high-risk group, with the ESC identifying the risk of dissection during pregnancy for this group as approximately 10 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/American",
"    </span>",
"    Association of Thoracic Surgeons (AATS) guidelines for the thoracic aorta note that it is reasonable to prophylactically replace the aortic root and ascending aorta if the aortic diameter exceeds 40 mm in women with MFS who are contemplating pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ]. Earlier American and Canadian guidelines had suggested that a diameter &gt;45 mm as an indication for elective repair prior to conception [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Although the risk is reduced with successful surgical correction, subsequent pregnancies are still associated with risk of aortic dissection in the remaining aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with a previous aortic dissection are particularly concerning and likely at high risk for complications during pregnancy, but there are insufficient data for quantifying their risk. One series included two women with a previous aortic dissection, one of whom developed another dissection during pregnancy despite having undergone aortic root replacement after the first episode [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the risk of complications during pregnancy, limited data suggest that pregnancy may increase the long-term rate of aortic dilatation in women with pre-existing dilation. The impact of pregnancy on the rate of aortic root growth was evaluated in a prospective study of 45 women with MFS: 23 women with 33 pregnancies and a control group of 22 childless women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/9\">",
"     9",
"    </a>",
"    ]. Aortic root diameter growth rate was similar in the pregnancy and control groups for those with baseline aortic root diameter &lt;40 mm, but was significantly greater in the pregnancy group than in controls for the nine women with baseline aortic root aortic root diameters 40 to 45 mm (0.36 versus 0.14 mm per year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MANAGEMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among women with MFS who become pregnant, a multidisciplinary approach to prenatal care is recommended, preferably at a center with experience in the management of patients with MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serial clinical assessment should include echocardiographic monitoring in all pregnant women with MFS, even among women with baseline aortic root diameter &le;40 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines recommend monthly or bimonthly echocardiographic measurement of the ascending aortic dimensions throughout pregnancy for all pregnant women with known aortic root or ascending aortic dilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ]. The frequency of clinical and imaging follow-up should be individualized depending on patient and aorta characteristics.",
"   </p>",
"   <p>",
"    If an aortic root diameter greater than 45 mm is detected during pregnancy, some authorities recommend consideration of termination of pregnancy, if prior to viability, and prompt aortic repair, although this approach is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/7\">",
"     7",
"    </a>",
"    ]. Prompt repair is less controversial if serial imaging studies demonstrate progressive dilatation over time [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/7\">",
"     7",
"    </a>",
"    ]. The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines note that prophylactic surgery may be considered if progressive aortic dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    worsening aortic valve regurgitation are documented [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted in the 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines, for pregnant women with aortic arch, descending or abdominal aortic dilatation, magnetic resonance imaging is recommended over computed tomography to avoid exposing the mother and fetus to ionizing radiation. Magnetic resonance imaging without gadolinium contrast is preferred and is generally sufficient for monitoring aortic size, although limited data suggest that the fetal risk of gadolinium may be minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/11\">",
"     11",
"    </a>",
"    ]. Transesophageal echocardiography is an alternative for imaging the thoracic aorta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     How to measure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement conventions differ for echocardiography as compared to computed tomography (CT) or magnetic resonance (MR) imaging. The internal aortic diameter is measured on echocardiography while CT and MR measure the external diameter (which is expected to be 2 to 4 mm larger than the internal diameter) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ]. The external diameter is the measurement generally used to determine the threshold for surgical repair. Since normal aortic dimensions vary with age and body surface area, these parameters should be taken into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beta blockers should be given to all MFS patients in an attempt to minimize aortic dilatation and risk of aortic dissection during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/7,12\">",
"     7,12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    is the preferred beta blocker in pregnant women since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    may impair fetal growth. The dose should be adjusted to maintain the heart rate no higher than 110",
"    <span class=\"nowrap\">",
"     beats/minute",
"    </span>",
"    after submaximal exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strict blood pressure control to prevent Stage II hypertension (systolic &ge; 160 mmHg or diastolic &ge; mmHg) is recommended for all pregnant patients with MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ]. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers are teratogens and thus contraindicated during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is optional at delivery (unless bacteremia is suspected) for patients with prior valve replacement surgery or prior endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with MFS with aortic root aneurysm (aortic root &gt;40 mm) should be delivered at an institution where cardiothoracic surgery is available [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obstetric complications appear to be increased in women with MFS. This was illustrated in a retrospective multicenter study of 111 completed pregnancies among 63 women with MFS [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/14\">",
"     14",
"    </a>",
"    ]. There was a high rate of premature deliveries (15 percent), mainly due to preterm premature rupture of membranes and cervical insufficiency, and a markedly increased combined rate of fetal and neonatal mortality (7 percent). For comparison, in the US general population the preterm birth rate is about 12 percent, neonatal mortality is about 0.4 percent and fetal mortality is about 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/15\">",
"     15",
"    </a>",
"    ]. Postpartum hemorrhage and uterine inversion have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have an aortic root diameter that remains &le;40 mm and have no heart failure resulting from valvular regurgitation may proceed with a vaginal delivery if there are no other obstetrical indications for cesarean delivery. With vaginal delivery, epidural anesthesia to minimize pain, forceps or vacuum delivery without maternal pushing, and continued use of a beta blocker during labor are appropriate ancillary measures to minimize surges in blood pressure and cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3657?source=see_link\">",
"     \"Obstetric anesthetic management of women with acquired or congenital heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to attempting epidural anesthesia, the possible presence of dural ectasia should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/17\">",
"     17",
"    </a>",
"    ]. Dural sac dilation can be present in up to 90 percent of patients with Marfan syndrome and may be associated with low back pain, headache, or proximal leg pain, weakness or numbness. If suspected, dural ectasia should be evaluated by lumbosacral magnetic resonance imaging or computerized tomography. Although dural ectasia is not an absolute contraindication for epidural anesthesia, the increased risk of dural puncture or inadequate anesthesia should be discussed with the patient. It has been recommended that the epidural technique be performed in the lateral decubitus position to decrease the possibility of extension of the ectatic dural sac into the epidural space [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/18\">",
"     18",
"    </a>",
"    ]. It is important to recognize that an increased amount of cerebrospinal fluid volume may be present with dural ectasia, which may lead to spinal anesthesia failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cesarean delivery is preferred in patients with an aortic diameter &gt;40 mm, aortic dissection, severe aortic regurgitation or heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/2,8,12\">",
"     2,8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis and management of aortic dissection that occurs during pregnancy are similar to that for aortic dissection in general.",
"   </p>",
"   <p>",
"    Given the lethal nature of aortic dissection, prompt diagnosis and intervention are critical. Due to concerns about ionizing radiation (CT) during pregnancy, transesophageal echocardiogram may be the initial diagnostic modality assuming availability. MRI aortic imaging is an option if immediately available [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Magnetic resonance imaging without gadolinium contrast is preferred although gadolinium may be appropriate if it enhances the clarity of the diagnosis. Limited data suggest that the fetal risk of gadolinium may be minimal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/11\">",
"     11",
"    </a>",
"    ]. However, prompt and urgent diagnosis is the first objective and the availability, reliability and speed of CT often make this the test of choice in pregnant patients presenting with a high clinical suspicion for aortic dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link\">",
"     \"Diagnostic imaging procedures during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"     \"Management of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal treatment of aortic dissection during pregnancy includes a high-risk maternal-fetal medicine team and an aortic specialty team with medical, percutaneous, and surgical aortic treatment capabilities.",
"   </p>",
"   <p>",
"    The 2010",
"    <span class=\"nowrap\">",
"     ACC/AHA/AATS",
"    </span>",
"    guidelines include the following recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For Type A (ascending aorta) dissection during the first or second trimester, urgent surgical repair with aggressive fetal monitoring when feasible is preferred. Fetal loss is common during hypothermia and prolonged cardiopulmonary bypass and there is an increased rate of teratogenesis [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20262/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For Type A dissection during the third trimester, urgent cesarean delivery followed by aortic repair is suggested.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For acute arch or Type B aortic dissection, medical therapy is preferred unless intervention (percutaneous stent or surgery) is required to treat malperfusion, aortic rupture, or subacute aortic leaking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"     \"Management of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacologic interventions to reduce shear stress and blood pressure are needed but the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    during pregnancy should be avoided when feasible in order to avoid possible fetal thiocyanate toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=see_link\">",
"       \"Patient information: Marfan syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with MFS should receive pregnancy counseling. They should understand that aortic rupture or dissection can occur during pregnancy at any root size. In addition, genetic counseling should be provided to potential parents. A multidisciplinary approach at a center with experience in management of MFS is recommended for all women with MFS who become pregnant. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with MFS who are contemplating pregnancy should have comprehensive aortic imaging, including a transthoracic echocardiogram. An aortic root diameter &gt;40 mm identifies a high-risk group, with the risk of dissection during pregnancy estimated as 10 percent. Pregnancy is discouraged with aortic root diameters &gt;45 mm unless elective repair is performed prior to conception. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Assessment of risk of aortic dissection/rupture'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women with MFS should undergo serial echocardiography to assess ascending aortic size. Those with an aortic diameter &gt;40 mm or those with evidence of aortic enlargement during pregnancy should undergo monthly or bimonthly evaluation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an aortic root diameter &gt;45 mm is detected during pregnancy, some authorities recommend consideration of termination of pregnancy and prompt aortic repair, although this approach is controversial. Prompt repair is less controversial if serial imaging studies demonstrate progressive dilatation over time. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Beta blocker, preferably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"       labetalol",
"      </a>",
"      should be used throughout pregnancy in an attempt to minimize aortic dilatation and the risk of aortic dissection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Management during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MFS who have an aortic root diameter that remains &le;40 mm and have no heart failure may proceed with a vaginal delivery if there are no other obstetrical indications for cesarean delivery. Cesarean delivery is preferred in patients with an aortic diameter &gt;40 mm, aortic dissection, severe aortic regurgitation or heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/1\">",
"      Meijboom LJ, Nollen GJ, Merchant N, et al. Frequency of coronary ostial aneurysms after aortic root surgery in patients with the Marfan syndrome. Am J Cardiol 2002; 89:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/2\">",
"      Elkayam U, Ostrzega E, Shotan A, Mehra A. Cardiovascular problems in pregnant women with the Marfan syndrome. Ann Intern Med 1995; 123:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/3\">",
"      Rossiter JP, Repke JT, Morales AJ, et al. A prospective longitudinal evaluation of pregnancy in the Marfan syndrome. Am J Obstet Gynecol 1995; 173:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/4\">",
"      Lipscomb KJ, Smith JC, Clarke B, et al. Outcome of pregnancy in women with Marfan's syndrome. Br J Obstet Gynaecol 1997; 104:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/5\">",
"      Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/6\">",
"      Therrien J, Gatzoulis M, Graham T, et al. Canadian Cardiovascular Society Consensus Conference 2001 update: Recommendations for the Management of Adults with Congenital Heart Disease--Part II. Can J Cardiol 2001; 17:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/7\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/8\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/9\">",
"      Meijboom LJ, Vos FE, Timmermans J, et al. Pregnancy and aortic root growth in the Marfan syndrome: a prospective study. Eur Heart J 2005; 26:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/10\">",
"      Lupton M, Oteng-Ntim E, Ayida G, Steer PJ. Cardiac disease in pregnancy. Curr Opin Obstet Gynecol 2002; 14:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/11\">",
"      De Santis M, Straface G, Cavaliere AF, et al. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol Scand 2007; 86:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/12\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     Wright, MJ, Dietz, HC, III. Connective tissue diseases. In: Oski's Principles and Practice of Pediatrics, McMillan, J, Oski, F (Eds), Lippincott Raven, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/14\">",
"      Meijboom LJ, Drenthen W, Pieper PG, et al. Obstetric complications in Marfan syndrome. Int J Cardiol 2006; 110:53.",
"     </a>",
"    </li>",
"    <li>",
"     www.cdc.gov (Accessed on April 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/16\">",
"      Rahman J, Rahman FZ, Rahman W, et al. Obstetric and gynecologic complications in women with Marfan syndrome. J Reprod Med 2003; 48:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/17\">",
"      Houston L, Tuuli M, Macones G. Marfan syndrome and aortic dissection in pregnancy. Obstet Gynecol 2011; 117:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/18\">",
"      Buser RT, Mordecai MM, Brull SJ. Combined spinal-epidural analgesia for labor in a patient with Marfan's syndrome. Int J Obstet Anesth 2007; 16:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/19\">",
"      Lacassie HJ, Millar S, Leithe LG, et al. Dural ectasia: a likely cause of inadequate spinal anaesthesia in two parturients with Marfan's syndrome. Br J Anaesth 2005; 94:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/20\">",
"      Gebker R, Gomaa O, Schnackenburg B, et al. Comparison of different MRI techniques for the assessment of thoracic aortic pathology: 3D contrast enhanced MR angiography, turbo spin echo and balanced steady state free precession. Int J Cardiovasc Imaging 2007; 23:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/21\">",
"      Krishnam MS, Tomasian A, Malik S, et al. Image quality and diagnostic accuracy of unenhanced SSFP MR angiography compared with conventional contrast-enhanced MR angiography for the assessment of thoracic aortic diseases. Eur Radiol 2010; 20:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20262/abstract/22\">",
"      Parry AJ, Westaby S. Cardiopulmonary bypass during pregnancy. Ann Thorac Surg 1996; 61:1865.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8129 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20262=[""].join("\n");
var outline_f19_50_20262=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSESSMENT OF RISK OF AORTIC DISSECTION/RUPTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MANAGEMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - How to measure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=related_link\">",
"      Management of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3657?source=related_link\">",
"      Obstetric anesthetic management of women with acquired or congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/11/25778?source=related_link\">",
"      Patient information: Marfan syndrome (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_50_20263="Ultrasound of appendicitis child";
var content_f19_50_20263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52767&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ultrasound of appendicitis in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Saggital (upper image) and transverse (lower image) ultrasound images of the right lower quadrant in a 4-year-old boy with fever, leucocytosis and acute right lower quadrant pain show an enlarged (8 mm), fluid filled, blind ending tubular structure surrounded by brightly echogenic, edematous mesenteric fat.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George A Taylor, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20263=[""].join("\n");
var outline_f19_50_20263=null;
var title_f19_50_20264="Posterior compartment forearm muscles";
var content_f19_50_20264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 578px\">",
"   <div class=\"ttl\">",
"    Muscles of the posterior compartment of the forearm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 558px; height: 678px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagrams above show the location of the muscles of the forearm's posterior compartment. Red represents a muscle's origin and blue a muscle's insertion.",
"    <div class=\"footnotes\">",
"     * Outcropping muscles of deep layer.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AR. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20264=[""].join("\n");
var outline_f19_50_20264=null;
var title_f19_50_20265="Effects of exercise in diabetes mellitus in adults";
var content_f19_50_20265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Effects of exercise in diabetes mellitus in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20265/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20265/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20265/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20265/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20265/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/50/20265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is being increasingly promoted as part of the therapeutic regimen for diabetes mellitus. In addition to its cardiovascular benefits, exercise can also improve glycemic control. The beneficial effect on glycemic control largely results from increased tissue sensitivity to insulin.",
"   </p>",
"   <p>",
"    To understand how these changes occur, it is helpful to begin by briefly reviewing the short- and long-term effects of exercise in normal individuals. Subsequently, the benefits of exercise in patients with type 1 and 2 diabetes and a program for physical activity will be reviewed in this topic card.",
"   </p>",
"   <p>",
"    The glycemic benefits of combined diet and exercise interventions in patients with diabetes, exercise for the prevention of type 2 diabetes, and sample cases illustrating problems that can occur when exercise is performed in patients treated with an intensive insulin regimen are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Intensive lifestyle modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H11#H11\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Exercise'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12402?source=see_link\">",
"     \"Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXERCISE AND MUSCLE METABOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise has both short-term and long-term effects on metabolism in nondiabetic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Short-term effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a person exercises, the muscles initially use glucose in the muscle and later convert muscle glycogen to glucose to provide energy. An average 70 kg adult man has approximately 1100 kcal stored as muscle glycogen and another 400 to 500 kcal stored as liver glycogen. Skeletal muscle differs from liver in that it lacks the enzyme glucose-6-phosphatase, which converts glucose-6-phosphate (derived from glycogen) to glucose; as a result, muscle glycogen can only be used as an energy source for muscle via the metabolism of glucose-6-phosphate to pyruvate. Glucose cannot be transferred out of muscle to prevent hypoglycemia (",
"    <a class=\"graphic graphic_figure graphicRef68962 \" href=\"UTD.htm?29/3/29757\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to utilizing muscle glycogen, exercising muscle also takes up glucose from the circulation, a process that requires the availability of insulin. As the blood glucose concentration begins to fall, the secretion of insulin decreases while that of glucagon rises. The net effect is increased hepatic glucose production due both to glycogenolysis and to gluconeogenesis, in which glucose is formed from lactate, pyruvate, alanine and other amino acids, and glycerol (",
"    <a class=\"graphic graphic_figure graphicRef68962 \" href=\"UTD.htm?29/3/29757\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the exercise continues, counterregulatory hormones other than glucagon (epinephrine, norepinephrine, growth hormone, and cortisol) play an increasing role. Epinephrine and norepinephrine stimulate hepatic glucose production to some extent, but their major effect is to stimulate lipolysis. Triglycerides are broken down into both free fatty acids, which are utilized as fuel by exercising muscles, and glycerol, which can be converted to glucose in the liver. These changes in hormone release and muscle metabolism become more pronounced with prolonged exercise: insulin secretion continues to fall, while there is a further increase in the release of the counterregulatory hormones. The net effect is a gradual reduction in muscle glucose uptake combined with stimulation of lipolysis and increased free fatty acid uptake by muscle (",
"    <a class=\"graphic graphic_figure graphicRef77664 \" href=\"UTD.htm?13/27/13758\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Long-term training effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate aerobic exercise on a regular, long-term basis has several effects on muscle function that lead to more efficient use of energy. These changes include increases in the quantity of mitochondrial enzymes and the number of \"slow-twitch\" muscle fibers, and the development of new muscle capillaries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/3\">",
"     3",
"    </a>",
"    ]. There is also increased translocation of insulin-responsive glucose transporters (GLUT4) from intracellular stores to the cell surface. GLUT4 promotes glucose uptake, which probably explains the overall increase in insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several types of exercise, including traditional aerobic, resistance, and high intensity low-volume training, have been shown to improve skeletal muscle adaptation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/3,5-8\">",
"     3,5-8",
"    </a>",
"    ]. Exercise, without weight loss, also appears to increase lipid metabolism. In a study of 18 sedentary nondiabetic adults doing moderate-intensity exercise for six months, the increase in insulin sensitivity was associated with a significant increase in postheparin plasma lipase and hepatic lipase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/9\">",
"     9",
"    </a>",
"    ]. The increase in the former correlated with a decrease in waist circumference and in body mass index. There is a graded relationship between exercise and improvements in serum lipid profiles. In a study of 111 sedentary, overweight men and women with mild to moderate dyslipidemia, those who exercised the most had the greatest improvements in serum lipid concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/10\">",
"     10",
"    </a>",
"    ]. This effect was independent of change in body weight. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17015?source=see_link\">",
"     \"Effects of exercise on lipoproteins and hemostatic factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EXERCISE IN DIABETIC ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in normal individuals, exercise has both short- and long-term effects on carbohydrate metabolism in diabetic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Short-term effects in type 1 and 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with type 2 diabetes, short-term exercise training improves insulin sensitivity as it does in nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In patients with type 2 diabetes treated with an oral hypoglycemic drug, exercise tends to lower blood glucose concentrations. However, this effect may depend upon the timing of the patients' last meal. In one study, there was no change in blood glucose concentrations in patients who were fasting before exercise, but the concentrations decreased in patients who exercised after eating [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic responses to exercise are modified in patients with type 1 diabetes, depending upon the serum insulin concentration at the time of exercise and upon the site and timing of recent insulin injections. Well-controlled type 1 diabetic patients with adequate serum insulin concentrations will usually have a fall in blood glucose concentrations that is much larger than that in normal individuals (",
"    <a class=\"graphic graphic_figure graphicRef60391 \" href=\"UTD.htm?36/39/37502\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/15\">",
"     15",
"    </a>",
"    ]. Several factors contribute to this response:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exogenous insulin cannot be shut off, thereby maintaining muscle glucose uptake and inhibiting hepatic glucose output.",
"     </li>",
"     <li>",
"      The increased temperature and blood flow associated with exercise may speed insulin absorption from subcutaneous depots, resulting in higher serum insulin concentrations. This effect is most prominent if the injection was recent, was given into an arm or leg that is being exercised [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/16\">",
"       16",
"      </a>",
"      ], or was inadvertently given intramuscularly [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, exercise can cause a paradoxical elevation in blood glucose concentrations in diabetic patients with poor metabolic control (blood glucose concentration above 250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [14",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    hypoinsulinemia, and some ketonuria. In these patients, the following factors come into play:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lack of insulin impairs glucose uptake by muscles and cannot prevent an increase in hepatic glucose output that is mediated by counterregulatory hormones, particularly epinephrine, cortisol, and growth hormone. These hormonal changes also lead sequentially to increased lipolysis and enhanced conversion of the free fatty acids to ketones (",
"      <a class=\"graphic graphic_figure graphicRef60391 \" href=\"UTD.htm?36/39/37502\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Long-term effects in type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term effects of exercise are somewhat different in patients with type 1 and type 2 diabetes. At baseline, patients with type 2 diabetes have impaired exercise capacity, due primarily to age and increased body mass index. In addition, exercise capacity in type 2 diabetes is affected by subclinical left ventricular dysfunction and cardiac autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/18\">",
"     18",
"    </a>",
"    ]. Other factors that may contribute to impaired exercise capacity have been proposed, including reduced skeletal muscle oxidative capacity due to mitochondrial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with type 2 diabetes are insulin-resistant, an effect that can be mediated by several different defects in glucose metabolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .) The defects include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decreased number and function of both insulin receptors and glucose transporters",
"     </li>",
"     <li>",
"      Decreased activity of some intracellular enzymes (including pyruvate dehydrogenase and glycogen synthetase)",
"     </li>",
"     <li>",
"      A low maximal oxygen uptake (VO2max) during exercise",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some of these defects improve during exercise training programs lasting 2 to 24 weeks. The favorable changes include increased activity of mitochondrial enzymes (thereby improving muscle energetics), increased insulin sensitivity, and muscle capillary recruitment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/8,11,23-25\">",
"     8,11,23-25",
"    </a>",
"    ]. There is, however, little or no increase in the number of muscle capillaries in patients with type 2 diabetes and microvascular complications [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of resistance training to aerobic exercise provides additional benefit for glucose disposal. As an example, in a study of 28 obese postmenopausal women with type 2 diabetes randomly assigned to no exercise, aerobic exercise alone or aerobic exercise plus resistance training, both exercise groups had reductions in abdominal and visceral adipose tissue, an increase in muscle density, and improvements in insulin sensitivity, compared with the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/26\">",
"     26",
"    </a>",
"    ]. The greatest improvement in insulin sensitivity was in the combined exercise group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glycemic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise improves glycemic control in patients with type 2 diabetes, as illustrated by the findings of several meta-analyses of trials examining the effect of exercise on glycemic control in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Exercise training reduces A1C values by approximately 0.5 to 0.7 percentage points compared with control participants.",
"   </p>",
"   <p>",
"    Some trials suggest that combined aerobic and resistance training may be superior to either exercise alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 251 adults with type 2 diabetes randomly assigned to resistance, aerobic, combined exercise, or control groups, all three exercise groups were associated with improvements in A1C compared with controls (absolute change in A1C -0.38 to -0.97 percentage points) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/31\">",
"       31",
"      </a>",
"      ]. The combined exercise program was associated with the greatest reduction in A1C (approximately one percentage point compared with controls). However, the combined program was also associated with a longer duration of exercise than the other groups, which may account for the greater improvement in glycemic control.",
"     </li>",
"     <li>",
"      In another trial of resistance training, aerobic exercise, combined aerobic and resistance training, or no exercise in 262 sedentary adults with type 2 diabetes, the duration of exercise (140 to 150",
"      <span class=\"nowrap\">",
"       minutes/week)",
"      </span>",
"      was similar in all exercise groups [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/32\">",
"       32",
"      </a>",
"      ]. After nine months, mean A1C decreased modestly in all exercise groups (-0.04 to -0.23 percentage points compared with a 0.11 percentage point increase in the control group). The absolute difference in A1C was significantly improved only in those assigned to the combined program compared with controls (between group difference 0.34 percent). The combined group also lost significantly more weight than the control and resistance training groups (-1.5, +0.4, and -0.3 kg, respectively), a finding that may account for the greater reduction in A1C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High intensity (low-volume) exercise may also improve glycemic control in patients with type 2 diabetes. In one study, seven adults with type 2 diabetes had continuous glucose monitoring for 24 hours on two separate days (exercise day and a control day) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/24,33\">",
"     24,33",
"    </a>",
"    ]. The exercise regimen consisted of cycling at 90 percent of individual maximal heart rate for 60 seconds, followed by 60 seconds of rest, repeated 10 times (total training session 20 minutes with 10 minutes of cycling and 10 minutes resting). The six patients who were taking oral agents continued them during the study. Several measures of glycemic control (three-hour postprandial glucose area under the curve, average post-meal peak glucose concentration, average blood glucose 60 to 120 minutes following meals, proportion of time spent in hyperglycemia) were significantly better on the exercise day. Twenty-four-hour average glucose tended to be lower (130 versus 140",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    on the control day [7.2 versus 7.8",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    but the difference was not statistically significant. Additional studies of this type of exercise training are needed in patients with type 2 diabetes, with longer term outcomes and in comparison to traditional forms of exercise.",
"   </p>",
"   <p>",
"    Thus, traditional aerobic, resistance, and possibly high intensity low-volume exercise regimens can improve glycemic control. When the duration of exercise is fixed (ie, 150",
"    <span class=\"nowrap\">",
"     minutes/week),",
"    </span>",
"    a combined program is optimal. Higher levels of exercise intensity are associated with greater improvements in A1C [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/30\">",
"     30",
"    </a>",
"    ]. In addition, long-term compliance is essential to achieve the glycemic benefits of exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Long-term compliance'",
"    </a>",
"    below.) Patients with diabetes are encouraged to perform at least 150 minutes of moderate-intensity aerobic exercise per week [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/35\">",
"     35",
"    </a>",
"    ]. In the absence of contraindications (ie, moderate to severe proliferative retinopathy), patients should be encouraged to perform resistance training (exercise with free weights or weight machines) at least twice per week. (See",
"    <a class=\"local\" href=\"#H24194821\">",
"     'A program for physical activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cardiovascular disease and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several randomized trials, exercise has been shown to improve cardiovascular risk factors (dyslipidemia, blood pressure, and body composition) in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/29\">",
"     29",
"    </a>",
"    ]. However, no clinical trials to date have demonstrated a reduction in major cardiovascular endpoints or mortality. In prospective cohort studies, exercise was associated with improvement in cardiovascular outcomes and a reduction in cardiovascular and overall mortality in type 2 diabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 5125 women who reported having type 2 diabetes in the Nurses' Health Study, the women who spent at least four hours per week performing moderate (including walking) or vigorous exercise had a 40 percent lower risk of developing cardiovascular disease (including coronary heart disease and stroke) than those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/38\">",
"       38",
"      </a>",
"      ]. This improvement in risk remained after adjustment for smoking, body mass index, and other cardiovascular risk factors.",
"     </li>",
"     <li>",
"      In a prospective cohort study of 2896 diabetic adults, those who walked for at least two hours per week had lower cardiovascular mortality rates when compared with inactive individuals (HR 0.66; 95% CI 0.45-0.96; 1.4 versus 2.1 percent per year, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/36\">",
"       36",
"      </a>",
"      ]. Rates were even lower for those who walked three to four hours per week (HR 0.47; 95% CI 0.24-0.91). The protective effect was independent of sex, age, race, body mass index, duration of diabetes, comorbid conditions, and physical limitations. The authors calculated that one death per year would be prevented for every 61 adults with diabetes who could be persuaded to walk at least two hours per week. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"       \"Exercise and fitness in the prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In meta-analyses of prospective cohort studies examining the impact of exercise and cardiorespiratory fitness on all-cause mortality in type 2 diabetes, compared with the lowest level of habitual physical activity, the highest level of physical activity was associated with lower overall mortality risk (RR 0.60, 95% CI 0.52-0.70) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/39,40\">",
"       39,40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Long-term compliance",
"    </span>",
"    &nbsp;&mdash;&nbsp;These beneficial effects have been hard to maintain for more than three months when implemented as fairly intensive programs requiring extra visits for special classes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As an example, in a 10-year study of 255 diabetic patients enrolled in a diabetes education program that emphasized exercise, compliance fell from 80 percent at six weeks to less than 50 percent at three months to less than 20 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/41\">",
"     41",
"    </a>",
"    ]. Studies using simple behavioral counseling by clinicians during routine clinic visits gave encouraging results [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], although long-term follow-up is not yet available.",
"   </p>",
"   <p>",
"    Several factors may contribute to the inability to sustain an exercise regimen in patients with type 2 diabetes. Most patients are trying to change a lifetime of sedentary behavior and continued compliance is a major problem [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/41\">",
"     41",
"    </a>",
"    ]. The Third National Health and Nutrition Examination Survey (NHANES III) found that most diabetic patients were physically inactive [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/45\">",
"     45",
"    </a>",
"    ]. Of 1480 diabetic adults, 31 percent reported no physical activity at all, and another 38 percent reported less than the recommended levels of activity.",
"   </p>",
"   <p>",
"    In addition to decreased exercise capacity, occult coronary or peripheral vascular disease or diabetic neuropathy can limit exercise tolerance.",
"   </p>",
"   <p>",
"    Despite these difficulties, maintenance of an exercise program in patients with type 2 diabetes remains a worthwhile goal because compliance is associated with long-term cardiovascular benefits and reduced mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Long-term effects in type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the response in type 2 diabetes, there is less evidence that regular exercise is associated with improved glycemic control in patients with type 1 diabetes, presumably due to the lesser importance of insulin resistance in these patients. In a meta-analysis of studies assessing the overall effects of exercise on chronic glycemic control, aerobic exercise (12 studies) was associated with improved glycemic control, whereas resistance training (two studies), combined aerobic and resistance training (four studies), and high intensity exercise (one study) did not significantly improve chronic glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be substantial beneficial effects of exercise on general well-being, hypertension, and other cardiovascular risk factors, independent of glycemic control.",
"   </p>",
"   <p>",
"    Patients with type 1 diabetes can tolerate even vigorous exercise, including participation in competitive triathlons and marathons [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The exercise should optimally be performed at the same time of day in relation to meals and insulin injections. When that is done, the change in blood glucose concentrations is usually remarkably predictable and reproducible [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As in adults with type 2 diabetes, adults with type 1 diabetes are encouraged to perform at least 150 minutes of moderate-intensity aerobic exercise per week [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/35\">",
"     35",
"    </a>",
"    ]. In the absence of contraindications (eg, moderate to severe proliferative retinopathy), patients should be encouraged to perform resistance training (exercise with free weights or weight machines) at least twice per week. (See",
"    <a class=\"local\" href=\"#H24194821\">",
"     'A program for physical activity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PREVENTION OF TYPE 2 DIABETES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the benefits of exercise in patients with diabetes, exercise may help prevent type 2 diabetes in patients at risk. The data supporting this conclusion are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link&amp;anchor=H11#H11\">",
"     \"Prediction and prevention of type 2 diabetes mellitus\", section on 'Exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194821\">",
"    <span class=\"h1\">",
"     A PROGRAM FOR PHYSICAL ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise is recommended for adults with type 1 and type 2 diabetes to improve glycemic control, assist with weight maintenance, and reduce the risk of cardiovascular disease and overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/50\">",
"     50",
"    </a>",
"    ]. There is no one exercise prescription for all individuals. Adults with diabetes are encouraged to perform 30 to 60 minutes of moderate-intensity aerobic activity (40 to 60 percent VO2 max) on most days of the week (at least 150 minutes of moderate-intensity aerobic exercise per week). In the absence of contraindications (eg, moderate to severe proliferative retinopathy), people with type 1 and 2 diabetes should also be encouraged to perform resistance training (exercise with free weights or weight machines) at least twice per week. As an alternative for physically fit patients, a shorter duration of more vigorous aerobic exercise (75 minutes per week of jogging 9.6",
"    <span class=\"nowrap\">",
"     km/hour)",
"    </span>",
"    may be preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9839763\">",
"    <span class=\"h2\">",
"     Evaluation prior to recommending an exercise regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that sudden exercise in sedentary subjects can precipitate myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. We typically perform a physical examination and a resting electrocardiogram (ECG) in sedentary adults (age &gt;50 years) with diabetes prior to beginning an exercise program. There are no randomized trial data to support the routine performance of exercise stress testing in asymptomatic patients with diabetes who are planning to begin an exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]. The vast majority of patients, particularly those with a sedentary lifestyle, are encouraged to begin a gentle exercise program and to gradually progress to a more vigorous program as tolerated. In addition, all cardiovascular disease risk factors (dyslipidemia, hypertension, smoking) should be evaluated and treated. Exercise stress testing for asymptomatic individuals at low risk of coronary artery disease is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]. However, it may be indicated for asymptomatic individuals at high risk for CHD (eg, evidence of peripheral or carotid atherosclerotic vascular disease, renal disease, abnormal resting electrocardiogram, multiple diabetes complications). The decision to perform stress testing prior to beginning an exercise program should be individualized.",
"   </p>",
"   <p>",
"    We do not typically perform exercise stress testing in asymptomatic patients as long as they are beginning a gentle exercise program with gradual progression as tolerated. However, the increased risk for asymptomatic coronary artery disease in those with diabetes and other risk factors suggests that an exercise tolerance test be considered prior to changing exercise levels in patients with diabetes who also have peripheral or carotid or coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of medical care in adults with diabetes mellitus\", section on 'Screening for coronary heart disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194398\">",
"    <span class=\"h2\">",
"     Type and frequency of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some form of regular exercise is likely to be beneficial in most patients with diabetes, even those with advanced, long-standing disease. We encourage patients with diabetes to perform 30 to 60 minutes of moderate-intensity aerobic activity on most days of the week. To increase compliance, the clinician should help the patient choose a type of exercise he or she will enjoy, and offer regular encouragement and suggestions for overcoming barriers to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. A reasonable initial regimen is 10 minutes of stretching and warm-up, followed by 20 minutes of gentle aerobic exercise such as walking, cycling, or rowing. The exercise should be performed regularly (at least three to five times per week) and preferably at the same time in relation to meals and insulin injections in patients treated with insulin. The duration and intensity of exercise should be increased gradually, as tolerated by the patient, to achieve a moderate intensity (eg, brisk walking). In the absence of contraindications (eg, moderate to severe proliferative retinopathy), people with type 1 and 2 diabetes should also be encouraged to perform resistance training (exercise with free weights or weight machines) at least twice per week. The exercises should include the large muscles of the core, upper, and lower body (approximately 10 repetitions per set).",
"   </p>",
"   <p>",
"    Similar benefits may be achieved with 75 minutes per week of more vigorous aerobic exercise (jogging 9.6",
"    <span class=\"nowrap\">",
"     km/hour)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1\">",
"     1",
"    </a>",
"    ]. This type of regimen may be an option for adults with diabetes who are generally fit and have higher aerobic capacity. Even shorter bouts of higher intensity exercise (&gt;75 percent VO2 max) have been advocated by some experts [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/54\">",
"     54",
"    </a>",
"    ]. With low-volume high intensity training, patients exercise more vigorously but for a reduced amount of time. An example of a low-volume high-intensity training program is cycling at 90 percent of individual maximal heart rate for 60 seconds, followed by 60 seconds of rest, repeated 10 times (total training session 20 minutes with 10 minutes of cycling and 10 minutes resting) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/5\">",
"     5",
"    </a>",
"    ]. The long-term health effects of low volume high-intensity training are unknown. This type of exercise regimen should only be used in adults who have been regularly exercising. Patients who are initiating an exercise program should begin with a gentle exercise program as described above with gradual progression as tolerated.",
"   </p>",
"   <p>",
"    The type of exercise may be limited by the presence of microvascular complications. There are occasional reports of patients with proliferative retinopathy developing retinal bleeding during vigorous exercise (involving Valsalva maneuvers), which have led many clinicians to advise caution with regard to intense isometric exercise (such as weight lifting) which can cause a marked increase in blood pressure that might precipitate intraocular bleeding in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1\">",
"     1",
"    </a>",
"    ]. Vigorous exercise of any type should be avoided in patients with recent or active retinal bleeding. Patients with neuropathy should avoid traumatic weight-bearing exercise (long distance running or prolonged downhill skiing) which may precipitate stress fractures in the small bones of the foot and ankle and the development of pressure ulcers on the toes and feet. Well-fitting protective footwear and comfortable shoes are also needed. Although exercise can transiently increase urinary protein excretion, there is no evidence that exercise increases progression of chronic kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/35\">",
"     35",
"    </a>",
"    ]. Thus, people with chronic kidney disease may engage in aerobic and resistance type exercise, as long as the exercise is started at a low intensity and volume and slowly increased as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20136?source=see_link\">",
"     \"Physical activity in end-stage renal disease and renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Heart Association, The American Diabetes Association, and The American College of Sports Medicine recommend at least 150 minutes of moderate-intensity aerobic activity (40 to 60 percent of maximal aerobic power [VO2 max]) per week for patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1,35,50\">",
"     1,35,50",
"    </a>",
"    ]. The activity should be distributed over at least three days each week, with no more than two consecutive days of inactivity. A larger amount of exercise (seven hours per week) may be beneficial for long-term maintenance of weight loss. Resistance training should be performed at least twice weekly [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/1,35\">",
"     1,35",
"    </a>",
"    ]. The US Department of Health and Human Services&rsquo; Physical Activity Guidelines for Americans suggest that adults do 150",
"    <span class=\"nowrap\">",
"     minutes/week",
"    </span>",
"    of moderate intensity, or at least 75 minutes of vigorous intensity, aerobic exercise per week, or combination of the two [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/55\">",
"     55",
"    </a>",
"    ]. They suggest that adults with chronic conditions follow the guidelines when possible, and if not possible, engage in regular physical activity according to their abilities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24194813\">",
"    <span class=\"h2\">",
"     Managing blood glucose during exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who take insulin (particularly those with type 1 diabetes), adjustments of their insulin regimen before, during, and after exercise are often empiric and aided by the results of self monitoring of blood glucose (SMBG). Vigorous exercise should be avoided in the presence of substantial hyperglycemia (&ge;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [13.9",
"    <span class=\"nowrap\">",
"     mmol/l])",
"    </span>",
"    or ketosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/15\">",
"     15",
"    </a>",
"    ]. It is not necessary to defer exercise based on milder hyperglycemia, as long as the patient feels well and there is no ketonemia or ketonuria. For insulin-requiring patients and for those taking insulin secretagogues (sulfonylureas, glinides), general considerations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fluid intake should be maintained at a relatively high level before, during, and after exercise.",
"     </li>",
"     <li>",
"      Measure the blood glucose before, during, and after exercise so that the changes in blood glucose can be documented and then predicted for subsequent exercise sessions [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12402?source=see_link&amp;anchor=H4#H4\">",
"       \"Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus\", section on 'Case 2'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the pre-exercise blood glucose is &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      ingest extra food, in the form of 15 to 30 grams of quickly absorbed carbohydrate (such as glucose tablets, hard candies, or juice), which should be taken 15 to 30 minutes before exercise and approximately every 30 minutes during exercise, based on repeat blood glucose testing during the exercise. Patients are also at risk of late hypoglycemia (ie, four to eight hours after the termination of exercise) due to replenishment of depleted glycogen stores. This can usually be avoided by ingesting slowly absorbed carbohydrates (dried fruit, fruit jerky, granola bars, or trail mix) immediately after exercise [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12402?source=see_link&amp;anchor=H6#H6\">",
"       \"Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus\", section on 'Case 3'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Inadequate replacement of carbohydrate before, during, and after exercise is the most common cause of exercise-associated hypoglycemia in patients taking insulin [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link&amp;anchor=H24#H24\">",
"       \"Management of hypoglycemia during treatment of diabetes mellitus\", section on 'Prevention of exercise-induced hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypoglycemia is uncommon in patients with type 2 diabetes not treated with insulin or insulin secretagogues (sulfonylureas, glinides) and, therefore, ingestion of extra carbohydrates is not typically required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional considerations for insulin-requiring patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease the insulin dose that affects time of the day when exercise will be performed by about 30 percent. This is especially important if exercise is of long duration (more than 60 minutes) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      To prevent increased insulin absorption, inject the insulin in a site other than the muscles to be exercised [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/16\">",
"       16",
"      </a>",
"      ]. As an example, the arm is a suitable site for cycling. On the other hand, the abdomen is preferred with tennis or racquetball where the exercise involves both the arms and legs. (Although absorption of insulin from the abdomen is faster than from the arm or leg in the resting state [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20265/abstract/58\">",
"       58",
"      </a>",
"      ], this difference is reversed with exercise.) It is also prudent to administer the insulin 60 to 90 minutes before exercise to minimize the problem of increased absorption.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"       \"Patient information: Type 2 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"       \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8492005\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In adults with diabetes, regular exercise is important to improve glycemic control, assist with weight maintenance, and reduce the risk of cardiovascular disease and overall mortality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Long-term effects in type 2 diabetes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Long-term effects in type 1 diabetes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24194821\">",
"       'A program for physical activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of adults, particularly those with a sedentary lifestyle, are encouraged to begin a gentle exercise program and to gradually progress to a more vigorous program as tolerated. In addition, all cardiovascular disease risk factors (dyslipidemia, hypertension, smoking) should be evaluated and treated. (See",
"      <a class=\"local\" href=\"#H9839763\">",
"       'Evaluation prior to recommending an exercise regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We do not typically perform exercise stress testing in asymptomatic patients as long as they are beginning a gentle exercise program with gradual progression as tolerated. However, the increased risk for asymptomatic coronary artery disease in those with diabetes and other risk factors suggests that an exercise tolerance test be considered prior to changing exercise levels in patients with diabetes who also have peripheral or carotid or coronary artery disease. (See",
"      <a class=\"local\" href=\"#H9839763\">",
"       'Evaluation prior to recommending an exercise regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults with diabetes are encouraged to perform at least 150 minutes of moderate-intensity (eg, brisk walking) aerobic exercise per week. In the absence of contraindications (eg, moderate to severe proliferative retinopathy), people with type 1 and 2 diabetes should also be encouraged to perform resistance training (exercise with free weights or weight machines) at least twice per week. For adults with diabetes who are generally fit and have higher aerobic capacity, a shorter duration of more vigorous aerobic exercise (75 minutes per week of jogging 9.6",
"      <span class=\"nowrap\">",
"       km/hour)",
"      </span>",
"      may be preferable. (See",
"      <a class=\"local\" href=\"#H24194398\">",
"       'Type and frequency of exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vigorous exercise should be avoided in the presence of ketosis. However, it is not necessary to defer exercise based on mild hyperglycemia (&lt;250 [13.9",
"      <span class=\"nowrap\">",
"       mmol/L]),",
"      </span>",
"      as long as the patient feels well and there is no ketonemia or ketonuria. (See",
"      <a class=\"local\" href=\"#H24194813\">",
"       'Managing blood glucose during exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fluid intake should be maintained at a relatively high level before, during, and after exercise. (See",
"      <a class=\"local\" href=\"#H24194813\">",
"       'Managing blood glucose during exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who take insulin (particularly those with type 1 diabetes), adjustments of their insulin regimen before, during, and after exercise are often empiric and aided by the results of self monitoring of blood glucose (SMBG). For patients who take insulin or insulin secretagogues (sulfonylureas, glinides), blood glucose should be measured before, during, and after exercise so that the changes in blood glucose can be documented and then predicted for subsequent exercise sessions. (See",
"      <a class=\"local\" href=\"#H24194813\">",
"       'Managing blood glucose during exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the pre-exercise blood glucose is &lt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.6",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      insulin- or insulin secretagogue-treated patients should ingest extra food, in the form of 15 to 30 grams of quickly absorbed carbohydrate (such as glucose tablets, hard candies, or juice), which should be taken 15 to 30 minutes before exercise and approximately every 30 minutes during exercise, based on repeat blood glucose testing during the exercise. Such patients are also at risk of late hypoglycemia (ie, four to eight hours after the termination of exercise) due to replenishment of depleted glycogen stores. (See",
"      <a class=\"local\" href=\"#H24194813\">",
"       'Managing blood glucose during exercise'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia is uncommon in patients with type 2 diabetes not treated with insulin or insulin secretagogues (sulfonylureas, glinides) and, therefore, ingestion of extra carbohydrates is not typically required. (See",
"      <a class=\"local\" href=\"#H24194813\">",
"       'Managing blood glucose during exercise'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/1\">",
"      Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes Care 2010; 33:e147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/2\">",
"      Abernethy PJ, Thayer R, Taylor AW. Acute and chronic responses of skeletal muscle to endurance and sprint exercise. A review. Sports Med 1990; 10:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/3\">",
"      Jensen TE, Richter EA. Regulation of glucose and glycogen metabolism during and after exercise. J Physiol 2012; 590:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/4\">",
"      McAuley KA, Williams SM, Mann JI, et al. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes Care 2002; 25:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/5\">",
"      Gibala MJ, Little JP, Macdonald MJ, Hawley JA. Physiological adaptations to low-volume, high-intensity interval training in health and disease. J Physiol 2012; 590:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/6\">",
"      Burgomaster KA, Howarth KR, Phillips SM, et al. Similar metabolic adaptations during exercise after low volume sprint interval and traditional endurance training in humans. J Physiol 2008; 586:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/7\">",
"      Little JP, Safdar A, Wilkin GP, et al. A practical model of low-volume high-intensity interval training induces mitochondrial biogenesis in human skeletal muscle: potential mechanisms. J Physiol 2010; 588:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/8\">",
"      Richards JC, Johnson TK, Kuzma JN, et al. Short-term sprint interval training increases insulin sensitivity in healthy adults but does not affect the thermogenic response to beta-adrenergic stimulation. J Physiol 2010; 588:2961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/9\">",
"      Duncan GE, Perri MG, Theriaque DW, et al. Exercise training, without weight loss, increases insulin sensitivity and postheparin plasma lipase activity in previously sedentary adults. Diabetes Care 2003; 26:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/10\">",
"      Kraus WE, Houmard JA, Duscha BD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med 2002; 347:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/11\">",
"      Phielix E, Meex R, Moonen-Kornips E, et al. Exercise training increases mitochondrial content and ex vivo mitochondrial function similarly in patients with type 2 diabetes and in control individuals. Diabetologia 2010; 53:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/12\">",
"      Winnick JJ, Sherman WM, Habash DL, et al. Short-term aerobic exercise training in obese humans with type 2 diabetes mellitus improves whole-body insulin sensitivity through gains in peripheral, not hepatic insulin sensitivity. J Clin Endocrinol Metab 2008; 93:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/13\">",
"      Kirwan JP, Solomon TP, Wojta DM, et al. Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 2009; 297:E151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/14\">",
"      Poirier P, Tremblay A, Catellier C, et al. Impact of time interval from the last meal on glucose response to exercise in subjects with type 2 diabetes. J Clin Endocrinol Metab 2000; 85:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/15\">",
"      Berger M, Berchtold P, C&uuml;ppers HJ, et al. Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 1977; 13:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/16\">",
"      Koivisto VA, Felig P. Effects of leg exercise on insulin absorption in diabetic patients. N Engl J Med 1978; 298:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/17\">",
"      Frid A, Ostman J, Linde B. Hypoglycemia risk during exercise after intramuscular injection of insulin in thigh in IDDM. Diabetes Care 1990; 13:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/18\">",
"      Fang ZY, Sharman J, Prins JB, Marwick TH. Determinants of exercise capacity in patients with type 2 diabetes. Diabetes Care 2005; 28:1643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/19\">",
"      Ritov VB, Menshikova EV, Azuma K, et al. Deficiency of electron transport chain in human skeletal muscle mitochondria in type 2 diabetes mellitus and obesity. Am J Physiol Endocrinol Metab 2010; 298:E49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/20\">",
"      Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 2002; 51:2944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/21\">",
"      Devlin JT. Effects of exercise on insulin sensitivity in humans. Diabetes Care 1992; 15:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/22\">",
"      Schneider SH, Amorosa LF, Khachadurian AK, Ruderman NB. Studies on the mechanism of improved glucose control during regular exercise in type 2 (non-insulin-dependent) diabetes. Diabetologia 1984; 26:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/23\">",
"      Henriksson J. Effects of physical training on the metabolism of skeletal muscle. Diabetes Care 1992; 15:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/24\">",
"      Little JP, Gillen JB, Percival ME, et al. Low-volume high-intensity interval training reduces hyperglycemia and increases muscle mitochondrial capacity in patients with type 2 diabetes. J Appl Physiol 2011; 111:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/25\">",
"      Womack L, Peters D, Barrett EJ, et al. Abnormal skeletal muscle capillary recruitment during exercise in patients with type 2 diabetes mellitus and microvascular complications. J Am Coll Cardiol 2009; 53:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/26\">",
"      Cuff DJ, Meneilly GS, Martin A, et al. Effective exercise modality to reduce insulin resistance in women with type 2 diabetes. Diabetes Care 2003; 26:2977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/27\">",
"      Boul&eacute; NG, Haddad E, Kenny GP, et al. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001; 286:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/28\">",
"      Snowling NJ, Hopkins WG. Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: a meta-analysis. Diabetes Care 2006; 29:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/29\">",
"      Chudyk A, Petrella RJ. Effects of exercise on cardiovascular risk factors in type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/30\">",
"      Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011; 305:1790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/31\">",
"      Sigal RJ, Kenny GP, Boul&eacute; NG, et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med 2007; 147:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/32\">",
"      Church TS, Blair SN, Cocreham S, et al. Effects of aerobic and resistance training on hemoglobin A1c levels in patients with type 2 diabetes: a randomized controlled trial. JAMA 2010; 304:2253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/33\">",
"      Gillen JB, Little JP, Punthakee Z, et al. Acute high-intensity interval exercise reduces the postprandial glucose response and prevalence of hyperglycaemia in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/34\">",
"      Gordon BA, Benson AC, Bird SR, Fraser SF. Resistance training improves metabolic health in type 2 diabetes: a systematic review. Diabetes Res Clin Pract 2009; 83:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/35\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/36\">",
"      Gregg EW, Gerzoff RB, Caspersen CJ, et al. Relationship of walking to mortality among US adults with diabetes. Arch Intern Med 2003; 163:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/37\">",
"      Tanasescu M, Leitzmann MF, Rimm EB, Hu FB. Physical activity in relation to cardiovascular disease and total mortality among men with type 2 diabetes. Circulation 2003; 107:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/38\">",
"      Hu FB, Stampfer MJ, Solomon C, et al. Physical activity and risk for cardiovascular events in diabetic women. Ann Intern Med 2001; 134:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/39\">",
"      Sluik D, Buijsse B, Muckelbauer R, et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis. Arch Intern Med 2012; 172:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/40\">",
"      Kodama S, Tanaka S, Heianza Y, et al. Association between physical activity and risk of all-cause mortality and cardiovascular disease in patients with diabetes: a meta-analysis. Diabetes Care 2013; 36:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/41\">",
"      Schneider SH, Khachadurian AK, Amorosa LF, et al. Ten-year experience with an exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992; 15:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/42\">",
"      Skarfors ET, Wegener TA, Lithell H, Selinus I. Physical training as treatment for type 2 (non-insulin-dependent) diabetes in elderly men. A feasibility study over 2 years. Diabetologia 1987; 30:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/43\">",
"      Long BJ, Calfas KJ, Wooten W, et al. A multisite field test of the acceptability of physical activity counseling in primary care: project PACE. Am J Prev Med 1996; 12:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/44\">",
"      Calfas KJ, Long BJ, Sallis JF, et al. A controlled trial of physician counseling to promote the adoption of physical activity. Prev Med 1996; 25:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/45\">",
"      Nelson KM, Reiber G, Boyko EJ, NHANES III. Diet and exercise among adults with type 2 diabetes: findings from the third national health and nutrition examination survey (NHANES III). Diabetes Care 2002; 25:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/46\">",
"      Tonoli C, Heyman E, Roelands B, et al. Effects of different types of acute and chronic (training) exercise on glycaemic control in type 1 diabetes mellitus: a meta-analysis. Sports Med 2012; 42:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/47\">",
"      Murillo S, Brugnara L, Novials A. One year follow-up in a group of half-marathon runners with type-1 diabetes treated with insulin analogues. J Sports Med Phys Fitness 2010; 50:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/48\">",
"      Boehncke S, Poettgen K, Maser-Gluth C, et al. [Endurance capabilities of triathlon competitors with type 1 diabetes mellitus]. Dtsch Med Wochenschr 2009; 134:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/49\">",
"      Temple MY, Bar-Or O, Riddell MC. The reliability and repeatability of the blood glucose response to prolonged exercise in adolescent boys with IDDM. Diabetes Care 1995; 18:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/50\">",
"      Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/51\">",
"      Mittleman MA, Maclure M, Tofler GH, et al. Triggering of acute myocardial infarction by heavy physical exertion. Protection against triggering by regular exertion. Determinants of Myocardial Infarction Onset Study Investigators. N Engl J Med 1993; 329:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/52\">",
"      Willich SN, Lewis M, L&ouml;wel H, et al. Physical exertion as a trigger of acute myocardial infarction. Triggers and Mechanisms of Myocardial Infarction Study Group. N Engl J Med 1993; 329:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/53\">",
"      Curfman GD. Is exercise beneficial--or hazardous--to your heart? N Engl J Med 1993; 329:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/54\">",
"      Bird SR, Hawley JA. Exercise and type 2 diabetes: new prescription for an old problem. Maturitas 2012; 72:311.",
"     </a>",
"    </li>",
"    <li>",
"     US Department of Health and Human Services. Physical Activity Guidelines for Americans: Summary. file://www.health.gov/paguidelines/guidelines/summary.aspx (Accessed on February 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/56\">",
"      Soo K, Furler SM, Samaras K, et al. Glycemic responses to exercise in IDDM after simple and complex carbohydrate supplementation. Diabetes Care 1996; 19:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/57\">",
"      Grimm JJ, Ybarra J, Bern&eacute; C, et al. A new table for prevention of hypoglycaemia during physical activity in type 1 diabetic patients. Diabetes Metab 2004; 30:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20265/abstract/58\">",
"      Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980; 92:59.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1777 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20265=[""].join("\n");
var outline_f19_50_20265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8492005\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXERCISE AND MUSCLE METABOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Short-term effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Long-term training effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EXERCISE IN DIABETIC ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Short-term effects in type 1 and 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Long-term effects in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glycemic control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cardiovascular disease and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Long-term compliance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Long-term effects in type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PREVENTION OF TYPE 2 DIABETES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24194821\">",
"      A PROGRAM FOR PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9839763\">",
"      Evaluation prior to recommending an exercise regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194398\">",
"      Type and frequency of exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24194813\">",
"      Managing blood glucose during exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8492005\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1777\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1777|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/3/29757\" title=\"figure 1\">",
"      Glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/27/13758\" title=\"figure 2\">",
"      Substrate use in exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/39/37502\" title=\"figure 3\">",
"      Exercise in T1DM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12402?source=related_link\">",
"      Cases illustrating the effects of exercise in intensive insulin therapy for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17015?source=related_link\">",
"      Effects of exercise on lipoproteins and hemostatic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36458?source=related_link\">",
"      Overview of medical care in adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/22/9572?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=related_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=related_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20136?source=related_link\">",
"      Physical activity in end-stage renal disease and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=related_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_50_20266="Diagnosis and acute management of suspected nephrolithiasis in adults";
var content_f19_50_20266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and acute management of suspected nephrolithiasis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Mark D Aronson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Glenn M Preminger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/50/20266/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/50/20266/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/50/20266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and ureteral stones are a common problem in primary care practice [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients may present with the classic symptoms of renal colic and hematuria. Others may be asymptomatic or have atypical symptoms such as vague abdominal pain, acute abdominal or flank pain, nausea, urinary urgency or frequency, difficulty urinating, penile pain, or testicular pain.",
"   </p>",
"   <p>",
"    Primary care clinicians need to be alert to the possibility of nephrolithiasis and its consequences to decide upon a diagnostic approach, therapy, and the need for referral to a urologist. These issues will be reviewed here. The epidemiology of nephrolithiasis and subsequent evaluation of such patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"     \"The first kidney stone and asymptomatic nephrolithiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eighty percent of patients with nephrolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The other main types include uric acid, struvite (magnesium ammonium phosphate), and cystine stones. The same patient may have more than one type of stone concurrently (eg, calcium oxalate and uric acid) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are different theories regarding calcium stone formation. One theory is that stone formation occurs when normally soluble material (eg, calcium, oxalate) supersaturates the urine and begins the process of crystal formation (eg, calcium oxalate crystal). It is presumed that crystal aggregates become large enough to be anchored (usually at the end of the collecting ducts), and then slowly increase in size over time. This anchoring is thought to occur at sites of epithelial cell injury, perhaps induced by the crystals themselves.",
"   </p>",
"   <p>",
"    Another theory is that stone formation is initiated in the renal medullary interstitium [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Calcium phosphate crystals may form in the interstitium and eventually get extruded at the renal papilla, forming the classic Randall's plaque [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Calcium oxalate or calcium phosphate crystals may then deposit on top of this nidus, remaining attached to the papilla.",
"   </p>",
"   <p>",
"    The pathogenesis of struvite, cystine, and uric acid stones is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of nephrolithiasis is influenced by urine composition, which can be affected by certain diseases and patient habits. For calcium oxalate stones, urinary risk factors include hypercalciuria, hyperoxaluria, hypocitraturia, and dietary risk factors such as a low calcium intake, high oxalate intake, high animal protein intake, high sodium intake, or low fluid intake (",
"    <a class=\"graphic graphic_table graphicRef78303 \" href=\"UTD.htm?1/35/1596\">",
"     table 1",
"    </a>",
"    ). Increased intake of Vitamin C has been associated with a higher risk of stones in men [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H15#H15\">",
"     \"Risk factors for calcium stones in adults\", section on 'Dietary risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are numerous other factors potentially associated with an increased risk of stone formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of prior nephrolithiasis. The rate of stone recurrence is 10 to 30 percent at three to five years among patients with idiopathic calcium oxalate stones [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. A higher recurrence rate of approximately 15 percent at one year, 35 to 40 percent at five years, and 50 percent at 10 years was found in another study, and was higher in men than women [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"       \"The first kidney stone and asymptomatic nephrolithiasis in adults\"",
"      </a>",
"      .) This variability is due, in part, to differences in sensitivity of different types of imaging studies.",
"     </li>",
"     <li>",
"      Patients with a family history of stones have an increased risk of nephrolithiasis. This was demonstrated in a report from the Health Professionals Follow-up Study, which found a greater than twofold increased risk of stone among individuals with a positive family history compared to those without such a history [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/12\">",
"       12",
"      </a>",
"      ]. Furthermore, a strong family history of nephrolithiasis in siblings can suggest the presence of rare inherited forms of nephrolithiasis, such as Dent's disease (a hypercalciuric form of nephrolithiasis), adenine phosphoribosyltransferase deficiency, and cystinuria [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. The diagnosis of cystinuria is suspected if the pathognomonic hexagonal cystine crystals are seen on urinalysis (",
"      <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"       \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"       \"Cystine stones\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      The risk of stones increases in individuals with enhanced enteric oxalate absorption (eg, gastric bypass procedures, bariatric surgery, short bowel syndrome). Studies suggest that even patients with \"modern\" bariatric surgery excrete higher levels of oxalate and have increased saturation of calcium oxalate salts than \"normal\" stone formers [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. A prospective trial of patients undergoing Roux-en-Y gastric bypass surgery demonstrated a significant increase in urinary oxalate excretion and increase in the relative supersaturation of calcium oxalate, suggesting an increased risk of stone formation [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Less common causes include frequent upper urinary tract infections (eg, as a result of spinal cord injuries) and use of medications that may crystallize in the urine such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"       indinavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/19-21\">",
"       19-21",
"      </a>",
"      ]. Nephrolithiasis has also been reported in children receiving prolonged",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"       \"Crystal-induced acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Stone disease is approximately twofold higher in patients with hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/23\">",
"       23",
"      </a>",
"      ]. Additional potential risk factors include diabetes, obesity, gout, and excessive physical exercise (including marathon running), which may increase crystalluria and possibly the risk of stones in predisposed individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/24-28\">",
"       24-28",
"      </a>",
"      ]. Studies suggest that changes in lifestyle and obesity have significantly increased the incidence of stones in women, thereby changing the previous gender ratio of male to female stone formation from 3:1 to 1.3 to 1.6:1 [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Low fluid intake is associated with increased stone risk. The type of fluid taken in may be important, although data are sometimes conflicting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H17#H17\">",
"       \"Risk factors for calcium stones in adults\", section on 'Type of fluid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A persistently acidic urine promotes uric acid precipitation, and leads to the formation of uric acid stones. An acidic urine is seen in chronic diarrheal states in which bicarbonate loss and volume depletion lead to a concentrated acid urine, or with other metabolic defects, including gout, diabetes, insulin resistance and obesity [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/28,31-35\">",
"       28,31-35",
"      </a>",
"      ]. In addition to having acidic urine, patients with gout and these other metabolic defects may have increased uric acid excretion, although they are typically so-called \"underexcretors of uric acid.\" (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"       \"Uric acid nephrolithiasis\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Struvite stones form in patients with an upper urinary tract infection due to a urease-producing organism such as Proteus or Klebsiella. Classic symptoms of nephrolithiasis are uncommon. The diagnosis is suggested in a patient with recurrent urinary tract infections, mild flank pain, or hematuria, who has a persistently alkaline urine pH (&gt;7.0), often with multiple magnesium ammonium phosphate crystals in the urine sediment (",
"      <a class=\"graphic graphic_picture graphicRef54594 \" href=\"UTD.htm?34/38/35439\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"       \"Pathogenesis and clinical manifestations of struvite stones\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may occasionally be diagnosed with asymptomatic nephrolithiasis when a radiologic imaging study of the abdomen is performed for other purposes or when surveillance imaging is done in those with a prior history of stones. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=see_link\">",
"     \"The first kidney stone and asymptomatic nephrolithiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The asymptomatic phase is more likely to persist in those who have never had a clinical episode of renal colic. A study of 107 patients with asymptomatic stones, for example, found that almost 70 percent remained symptom-free during the 31 months of follow-up; a linear association was noted between the development of a symptomatic event and the number of previous stones [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients occasionally present after having passed gravel or a stone. Uric acid stones are more likely to present with gravel, but they can also produce acute obstruction.",
"   </p>",
"   <p>",
"    Symptoms may develop when stones initially pass from the renal pelvis into the ureter. Pain is the most common symptom and varies from a mild and barely noticeable ache to discomfort that is so intense that it requires parenteral analgesics. The pain typically waxes and wanes in severity, and develops in waves or paroxysms that are related to movement of the stone in the ureter and associated ureteral spasm. Paroxysms of severe pain usually last 20 to 60 minutes. Pain is thought to occur primarily from urinary obstruction with distention of the renal capsule.",
"   </p>",
"   <p>",
"    The site of obstruction determines the location of pain. Upper ureteral or renal pelvic obstruction lead to flank pain or tenderness, whereas lower ureteral obstruction causes pain that may radiate to the ipsilateral testicle or labium. The location of the pain may change as the stone migrates. Many patients familiar with the symptoms are able to predict whether the stone has passed through the ureter. However, stones that are impacted and do not migrate cannot be localized with certainty based on symptoms alone. In addition, a variable location of pain can be misleading and occasionally mimics an acute abdomen or dissecting aneurysm. In some patients with chronic back pain, the diagnosis of acute colic may be difficult without an imaging study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gross or microscopic hematuria occurs in the majority of patients presenting with symptomatic nephrolithiasis (but is also often present in asymptomatic patients). Other than passage of a stone or gravel, this is the single most discriminating predictor of a kidney stone in patients presenting with unilateral flank pain. One study, for example, found that acute, unilateral flank pain, hematuria, and a positive plain film of the abdomen are present in 90 percent of patients presenting to an emergency department with a stone (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Diagnosis'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the absence of hematuria in the setting of acute flank pain does not exclude the presence of nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/3,38\">",
"     3,38",
"    </a>",
"    ]. Hematuria is not detected in approximately 10 to 30 percent of patients with documented nephrolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. One factor that may undermine the sensitivity of hematuria is the interval from the onset of acute pain to the time of urine examination. In a retrospective study of over 450 patients with CT-documented acute ureterolithiasis, hematuria was present in 95 percent on day one and 65 to 68 percent on days three and four [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other symptoms that are commonly seen include nausea, vomiting, dysuria, and urgency. The last two complaints typically occur when the stone is located in the distal ureter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrolithiasis may lead to persistent renal obstruction, which could cause permanent renal damage if left untreated.",
"   </p>",
"   <p>",
"    Staghorn calculi themselves do not typically produce symptoms unless the stone results in urinary tract obstruction or infection. However, they can lead to renal failure over years if they are present bilaterally. One study found that deterioration in renal function occurred in 28 percent of patients with staghorn calculi over an eight-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=see_link\">",
"     \"Pathogenesis and clinical manifestations of struvite stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several conditions may mimic renal colic due to nephrolithiasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bleeding within the kidney can produce clots that lodge temporarily in the ureter. Thus, renal cell carcinoma rarely presents with renal colic [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/42\">",
"       42",
"      </a>",
"      ]. In comparison, glomerular bleeding does not lead to clot formation or symptoms of renal colic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Glomerular versus nonglomerular bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pain due to an ectopic pregnancy can occasionally be mistaken for renal colic. The underlying cause of the pain can usually be clarified by obtaining a renal and a pelvic ultrasound [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with an aortic aneurysm are rarely misdiagnosed as having renal colic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"       \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute intestinal obstruction or appendicitis may present with colic but usually not in association with hematuria.",
"     </li>",
"     <li>",
"      Individuals seeking attention or narcotics may pretend to have renal colic and may have self-inflicted hematuria [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/44\">",
"       44",
"      </a>",
"      ]. In addition, there may be drug-seeking individuals who actually have stones, but they are in the kidney and not the ureter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differential diagnosis of abdominal discomfort is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nephrolithiasis is initially suspected by the clinical presentation. Possible confirmatory radiologic tests include abdominal plain film, intravenous pyelography (IVP), ultrasonography, and most commonly, non-contrasted helical CT scan, which is the test of choice (",
"    <a class=\"graphic graphic_table graphicRef65056 \" href=\"UTD.htm?18/51/19260\">",
"     table 2",
"    </a>",
"    ). It is important to appreciate that ureteral dilatation without a stone on radiologic examination could represent recent passage of a stone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Non-contrast helical CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A non-contrast helical CT can detect both stones and urinary tract obstruction, and has become the gold standard for the radiologic diagnosis of stone disease since stones not visualized on KUB or IVP will usually be detected by CT scan (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69052 graphicRef72669 \" href=\"UTD.htm?29/11/29878\">",
"     image 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. CT cuts that are 3 to 5 mm in thickness are optimal for the detection of stones. The specificity of helical CT is nearly 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]; thus, a positive study confirms the diagnosis of nephrolithiasis and patients should be treated appropriately. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Acute therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Furthermore, a CT scan in patients with a suspected kidney stone can define an alternate significant diagnosis. In one report of patients with their first episode of a suspected kidney stone, 33 percent had an alternate diagnosis not suspected on clinical grounds, one-half of whom had significant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The superiority of helical CT scan in identifying stones is illustrated in the following reports. In one study, an IVP and a non-contrast CT scan were performed in 20 patients with acute flank pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/51\">",
"     51",
"    </a>",
"    ]. Twelve were found to be obstructed; in five, the stone was seen on both IVP and CT, in six, the stone was seen only on CT scan, and one patient had no detectable stone. The sensitivity and specificity of non-contrast CT was 95 and 98 percent, respectively, in a study of 417 patients presenting with acute flank pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/48\">",
"     48",
"    </a>",
"    ]. A meta-analysis of four studies including 296 patients concluded that non-contrast helical CT is significantly better than IVP at diagnosing and excluding stones [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An important exception is nephrolithiasis secondary to HIV protease inhibitors, primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/19\">",
"     19",
"    </a>",
"    ]. These stones are not radiopaque and signs of obstruction may be minimal or absent; thus, the diagnosis may be missed with IVP, ultrasound, and non-contrasted CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/53\">",
"     53",
"    </a>",
"    ]. In such patients, contrast-enhanced CT scanning may be required to establish the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-contrast helical CT scan can also detect secondary signs of urinary tract obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. The likelihood of detecting these findings varies with the duration of pain. This was illustrated in a report of 227 patients with acute ureterolithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/54\">",
"     54",
"    </a>",
"    ]. Ureteral dilatation was seen in 84 and 97 percent at two and eight hours, respectively; collecting system dilatation in 68 and 89 percent at two and eight hours, respectively; and moderate to severe perinephric stranding in 5 and 51 percent at two and eight hours, respectively.",
"   </p>",
"   <p>",
"    A possible pitfall of CT scanning in patients who do not have evidence of urinary tract obstruction is the occasional inability to distinguish ureteral stones from phleboliths overlying the course of the ureter [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/55\">",
"     55",
"    </a>",
"    ]. This difficulty may be obviated by finding a \"rim\" sign on CT scanning due to circumferential edema from ureteral lithiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23999874\">",
"    <span class=\"h3\">",
"     Reducing radiation dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose non-contrast CT imaging allows identification of renal and ureteral calculi with similar sensitivity and specificity as standard CT scans but with significantly reduced radiation dosage [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, low dose non-contrast CT may be less reliable for detecting small stones (less than 2 mm in diameter).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725865\">",
"    <span class=\"h3\">",
"     Determination of stone composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stone density on CT scan as well as location",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general appearance may suggest the stone composition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although magnesium ammonium phosphate and cystine stones are often radio-opaque, they are not as dense as stones comprised of calcium oxalate or calcium phosphate",
"     </li>",
"     <li>",
"      Calcium phosphate stones are more likely found in the presence of nephrocalcinosis, which is suggestive of renal tubular acidosis. Bilateral calcifications at the corticomedullary junction is typically seen in medullary sponge kidney and, in this setting, calcium oxalate or calcium phosphate stones may be found (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76195 \" href=\"UTD.htm?15/54/16226\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The presence of large calculi in the renal pelvis favors struvite stones (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72669 \" href=\"UTD.htm?20/47/21233\">",
"       image 1B",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, although uric acid, cystine and struvite stones can usually be distinguished from calcium oxalate calculi, CT scanning is not yet sensitive enough to identify the different forms of calcium oxalate (ie, dihydrate versus monohydrate) or to distinguish calcium oxalate from calcium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Investigations with dual energy CT (DECT) suggest that this enhanced imaging modality, which utilizes two energy sources, may be more sensitive than standard helical CT for determining stone composition [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/63-66\">",
"     63-66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is the procedure of choice for patients who should avoid radiation, including pregnant women and possibly women of childbearing age. It is sensitive for the diagnosis of urinary tract obstruction and can detect radiolucent stones missed on KUB; however, ultrasonography may miss small stones and ureteral stones [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/67\">",
"     67",
"    </a>",
"    ]. Distal ureteral stones may be detected by transvaginal ultrasonography. The issue of nephrolithiasis complicating a pregnancy, including alternative studies if ultrasound is negative but the clinical suspicion remains high, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=see_link\">",
"     \"Nephrolithiasis during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of imaging modalities in combination frequently improves overall accuracy. In one study, the combination of ultrasonography and abdominal radiography provided somewhat comparable results to that observed with non-contrast helical CT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/68\">",
"     68",
"    </a>",
"    ]. Whether this combination is an alternative to CT when access to CT is limited requires further evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Abdominal plain film",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plain abdominal x-ray will identify sufficiently large radiopaque stones such as calcium, struvite, and cystine stones (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef62009 \" href=\"UTD.htm?42/7/43123\">",
"     image 3",
"    </a>",
"    ), but will miss radiolucent uric acid stones, may miss small stones or stones overlying bony structures, and will not detect obstruction. It is not the imaging modality of choice for initial diagnosis, although it may add to the sensitivity and specificity of an intravenous pyelogram [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/37\">",
"     37",
"    </a>",
"    ]. There is little role for an abdominal plain film when helical CT is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Intravenous pyelogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IVP has a higher sensitivity and specificity than an abdominal plain film for the detection of stones and provides data about the degree of obstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80493 \" href=\"UTD.htm?17/17/17694\">",
"     image 4",
"    </a>",
"    ). It was previously the diagnostic procedure of choice, but is no longer because of potential contrast reactions, lower sensitivity, and higher radiation exposure. It has been replaced by non-contrasted helical CT as the test of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging is rarely used during the management of stone disease, except in the evaluation of pregnant patients, because this modality is not optimal for identifying stones. Thus, this modality can be utilized if there is a specific indication to reduce radiation exposure (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=see_link\">",
"     \"Nephrolithiasis during pregnancy\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of nephrolithiasis should be suspected in all patients with the acute onset of atraumatic flank pain, particularly if without abdominal tenderness and with hematuria. The superior sensitivity and specificity of non-contrasted helical CT compared with KUB, IVP, and ultrasound suggest that it is now the initial diagnostic study of choice in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/3\">",
"     3",
"    </a>",
"    ]. A negative study should prompt consideration of a different diagnosis. IVP and ultrasonography are alternatives if helical CT is not available.",
"   </p>",
"   <p>",
"    Individual patient factors may influence the work-up in some instances [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ultrasound is the initial diagnostic test in pregnant women or in patients in whom cholecystitis or a gynecologic process is a prominent consideration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=see_link\">",
"       \"Nephrolithiasis during pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal plain film is a reasonable initial test in patients who have a history of radiopaque calculi and acute flank pain that is similar to that in previous episodes. However, a helical CT may be necessary if the abdominal plain film is negative, since the latter test may miss stones in the ureter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further evaluation consists of determining the predisposing factors to stone formation with blood tests and urine collections. This is an essential part of the evaluation, since therapy to prevent recurrent stone formation is determined by the biochemical abnormalities that are present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ACUTE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with acute renal colic can be managed conservatively with pain medication and hydration until the stone passes (",
"    <a class=\"graphic graphic_algorithm graphicRef83630 \" href=\"UTD.htm?14/52/15182\">",
"     algorithm 1",
"    </a>",
"    ). Most patients with acute renal colic can be managed conservatively with pain medication. Forced intravenous hydration does not seem to be more effective in reducing the amount of pain medication required or increasing stone passage compared with minimal intravenous hydration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urgent urologic consultation is warranted in patients with urosepsis, acute renal failure, anuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unyielding pain, nausea, or vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/2,71\">",
"     2,71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Urology consultation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The likelihood that ureteral stones will pass depends upon the size and location of the stone; smaller and more distal stones are more likely to pass without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Stone passage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Straining urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be instructed to strain their urine for several days and bring in any stone that passes for analysis. This will enable the clinician to better plan preventive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pain control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients can be managed at home if they are able to take oral medications and fluids. Hospitalization is required for those who cannot tolerate oral intake or who have uncontrollable pain or fever.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     NSAIDs and opioids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both nonsteroidal antiinflammatory drugs (NSAIDs) and opioids have traditionally been used for pain control in patients with acute renal colic. NSAIDs have the possible advantage of decreasing ureteral smooth muscle tone, thereby directly treating the mechanism by which pain is thought to occur (ureteral spasm) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective randomized controlled studies suggest that NSAIDs are at least as effective as opiates [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/3,76-78\">",
"     3,76-78",
"    </a>",
"    ]. This was illustrated in the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind study, 51 patients with renal colic were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      (100 mg) by rectal suppository or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      (5 mg loading dose and up to two additional 2.5 mg doses if needed) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/77\">",
"       77",
"      </a>",
"      ]. Morphine recipients reported more pain relief at 10 minutes, but there was no significant difference between the two groups by 20 to 30 minutes.",
"     </li>",
"     <li>",
"      Another randomized, double-blind trial found that intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"       ketorolac",
"      </a>",
"      (initial dose 60 mg) was associated with improved pain relief compared with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      (50 mg initial dose) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To better assess the relative efficacy of NSAIDs or opioids in the treatment of renal colic, a systematic review of 20 trials with 1613 participants was published in 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/79\">",
"     79",
"    </a>",
"    ]. Both NSAIDs and opioids had clinically significant analgesic benefits, including the ability to achieve complete short-term pain relief.",
"   </p>",
"   <p>",
"    Some relative benefits with NSAIDs may be a lower requirement for rescue analgesia and a lower incidence of adverse effects, particularly nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/79,80\">",
"     79,80",
"    </a>",
"    ]. In addition, treatment with NSAIDs discourages opiate-seeking patients who may spuriously present with symptoms of renal colic. On the other hand, in patients with preexisting renal disease or severe volume depletion, NSAIDs may interfere with the kidney's autoregulatory response to acute obstruction and induce acute renal failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial suggested that NSAIDs and opioids may be superior to either agent alone. Among 130 patients with renal colic, combination therapy with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (5 mg) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    (15 mg) was associated with a greater reduction in pain at 40 minutes compared with either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/80\">",
"     80",
"    </a>",
"    ]. In addition, patients who received combination therapy were more likely to have complete relief of pain at 20 minutes (30 versus 11 and 16 percent with ketorolac and morphine alone, respectively), and less likely to require rescue morphine (16 versus 33 and 42 percent, respectively). However, the relatively low dose of ketorolac used (standard dose is 30 mg), may have partially accounted for these results.",
"   </p>",
"   <p>",
"    NSAIDs should be stopped three days before anticipated shock wave lithotripsy to minimize the risk of bleeding. Standard doses of opiates will relieve pain in those who do not respond to NSAIDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stone passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stone size is the major determinant of the likelihood of spontaneous stone passage, although stone location is also important [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Most stones &le;5 mm in diameter pass spontaneously. For stones larger than 4 mm in diameter, there is a progressive decrease in the spontaneous passage rate, which is unlikely with stones &ge;10 mm in diameter. Proximal ureteral stones are also less likely to pass spontaneously.",
"   </p>",
"   <p>",
"    This was illustrated in a review of 75 patients with ureteral calculi, with the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/72\">",
"     72",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 41 patients with a stone diameter &le;2 mm, only two (5 percent) required intervention. The average time to stone passage in the remaining patients was 8.2 days, and 95 percent of stones passed in 31 days.",
"     </li>",
"     <li>",
"      Among 18 patients with a stone diameter between 2 and 4 mm, three (17 percent) required intervention. The average time to stone passage in the remaining patients was 12.2 days, and 95 percent of stones passed in 40 days.",
"     </li>",
"     <li>",
"      Among 16 patients with a stone diameter between 4 and 6 mm, eight (50 percent) required intervention. The average time to stone passage in the remaining patients was 22 days, and 95 percent of stones passed in 39 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in another report of 172 patients with ureteral stones [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/73\">",
"     73",
"    </a>",
"    ]. The likelihood of spontaneous stone passage was 87 percent for 1 mm stones, 76 percent of 2 to 4 mm stones, 60 percent for 5 to 7 mm stones, 48 percent for 7 to 9 mm stones, and 25 percent of stones &ge;9 mm. Spontaneous passage was also affected by stone location, ranging from 48 percent for stones in the proximal ureter to 79 percent of stones at the ureterovesical junction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Facilitating stone passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different medical interventions increase the passage rate of ureteral stones, including antispasmodic agents, calcium channel blockers, and alpha blockers, which have been used in combination with or without steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/81-90\">",
"     81-90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefits of medical therapy have been examined in meta-analyses, which have analyzed different agents [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/88,91\">",
"     88,91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a 2007 meta-analysis of 11 trials that enrolled 911 patients, ureteral stone passage was 44 percent more likely with alpha blocker therapy versus conservative therapy alone (95% CI 1.31-1.59) [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One 2006 meta-analysis of nine controlled trials included 693 patients with mean stone size between 3.8 and 7.8 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/88\">",
"       88",
"      </a>",
"      ]. Compared with the control group, patients treated with a calcium channel blocker (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ) or alpha blocker (usually",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      ) had a 65 percent greater likelihood of stone passage (95% CI 45-88 percent). In analyses of the individual agents, there was a 90 and 54 percent greater likelihood of stone passage with calcium channel blockers and alpha blockers, respectively, relative to controls.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies directly comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    have reported similar rates of stone passage or perhaps slightly higher rates with tamsulosin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/86-88,90\">",
"     86-88,90",
"    </a>",
"    ]. A potential advantage of tamsulosin is somewhat faster stone passage and fewer hospitalizations and procedures. Other alpha blockers appear to be similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/89,92\">",
"     89,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    International guidelines from the American Urological Association and the European Association of Urology on the management of ureteral calculi suggest that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"In a patient who has a newly diagnosed ureteral stone &lt;10 mm and whose symptoms are controlled, observation with periodic evaluation is an option for initial treatment. Such patients may be offered an appropriate medical therapy to facilitate stone passage during the observation period. In a choice between active stone removal and conservative treatment with medical expulsive therapy (MET), it is important to take into account all individual circumstances that may affect treatment decisions. A prerequisite for MET is that the patient is reasonably comfortable with that therapeutic approach and that there is no obvious advantage of immediate active stone removal\" [",
"      <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon data suggesting faster stone passage with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    , we initiate treatment with tamsulosin (0.4 mg once daily) for four weeks to facilitate spontaneous stone passage in patients with stones &le;10 mm in diameter. Patients are then re-imaged if spontaneous passage has not occurred.",
"   </p>",
"   <p>",
"    Patients will typically require analgesics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    . Concurrent antibiotics are used by some groups but have not been studied to determine their value in the setting of a patient receiving MET. Patients with stones larger than 10 mm in diameter, patients with significant discomfort, those with significant obstruction or who have not passed the stone after four to six weeks should be referred to urology for potential intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     UROLOGY CONSULTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent urologic consultation is warranted in patients with urosepsis, acute renal failure, anuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unyielding pain, nausea, or vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/3,69\">",
"     3,69",
"    </a>",
"    ]. Outpatient urology referral is indicated in patients with a stone &gt;10 mm in diameter and in patients who fail to pass the stone after a trial of conservative management, including medical expulsive therapy, particularly if the stone is &gt;4 mm in diameter or if there is uncontrolled pain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/74,94\">",
"     74,94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who do not pass the stone may need imaging if it has not already been performed. If only ultrasonography or IVP have been obtained and the stone has not been identified, a non-contrast helical CT should be performed.",
"   </p>",
"   <p>",
"    Current options for therapy of stones that do not pass include shock wave lithotripsy (SWL), ureteroscopic lithotripsy with electrohydraulic or laser probes, percutaneous nephrolithotomy and laparoscopic stone removal. Open surgical stone removal is rarely needed. SWL is the treatment of choice in 75 percent of patients and works best for stones in the renal pelvis and upper ureter. With the newer machines, most patients tolerate the procedure reasonably well. Approximately one-third have transient mild fever, with obstruction by the stone fragments or urinary tract infection occurring in less than 10 percent of cases. Both SWL and ureteroscopy are considered first-line management options for ureteral stones that require removal, with ureteroscopy yielding higher stone-free rates, but with an increased incidence of complications over shock wave lithotripsy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/50/20266/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with larger renal calculi (eg, &gt;1.5 cm), renal stones of harder composition (eg, cystine or calcium oxalate monohydrate) or stones in complex renal or ureteral locations (eg, lower pole calyx or mid-ureter), SWL is only successful in approximately 50 percent of cases. In these settings, endoscopic stone fragmentation with a percutaneous or ureteroscopic approach is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=see_link\">",
"     \"Management of ureteral calculi\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=see_link\">",
"     \"Renal complications of extracorporeal shock wave lithotripsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     EVALUATION AND SUBSEQUENT TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the acute stone episode is over and the stone, if retrieved, is sent for analysis, the patient should be evaluated for possible underlying causes of stone disease, including hypercalcemia (most often due to primary hyperparathyroidism), hypercalciuria, hyperuricosuria, hypocitraturia, hyperoxaluria, and urine volume. How and when this evaluation should be performed is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent therapy is based upon the type of stone and the biochemical abnormalities that are present. However, it remains uncertain whether evaluation and therapy are warranted after the first stone or only in patients with active stone disease, which is defined as the formation of new stones, increase in size of old stones, or the continued passage of gravel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=see_link\">",
"     \"Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once it has been determined that therapy to prevent new stone formation is required, the following guidelines can be used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients require increased fluid intake. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dietary recommendations tailored to the individual's habits and urine composition may be beneficial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with calcium stones who cannot be solely managed with dietary modifications can be treated with a thiazide diuretic and low sodium diet for hypercalciuria,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      for hyperuricosuria, and potassium citrate for hypocitraturia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with uric acid stones can be treated with potassium citrate to alkalinize the urine and occasionally",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      (for patients with severe hyperuricosuria). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"       \"Uric acid nephrolithiasis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with cystine stones can be treated with a high fluid intake, urinary alkalinization, and drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"       tiopronin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"       \"Cystine stones\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Struvite stones typically require complete stone removal with percutaneous nephrolithotomy and aggressive prevention and treatment of future urinary tract infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=see_link\">",
"       \"Management of struvite or staghorn calculi\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=see_link\">",
"       \"Patient information: Kidney stones in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=see_link\">",
"       \"Patient information: Kidney stones in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2698242\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eighty percent of patients with nephrolithiasis form calcium stones, most of which are composed primarily of calcium oxalate or, less often, calcium phosphate. The other main types include uric acid, struvite (magnesium ammonium phosphate), and cystine stones. A patient may have a stone with more than one component (eg, a stone containing both calcium oxalate and uric acid). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of nephrolithiasis is influenced by urine composition, which can be affected by certain diseases and patient habits. These are summarized in the following table (",
"      <a class=\"graphic graphic_table graphicRef78303 \" href=\"UTD.htm?1/35/1596\">",
"       table 1",
"      </a>",
"      ). In addition, patients with a personal or family history of kidney stones and those who have had certain types of bowel surgery (eg, gastric bypass, bariatric surgery, short bowel syndrome) are at high risk for nephrolithiasis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients may occasionally be diagnosed with asymptomatic nephrolithiasis when a radiologic imaging study of the abdomen is performed for other purposes or when surveillance imaging is done in those with a prior history of stones. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although stones (or gravel) may pass asymptomatically, symptoms may develop when stones initially pass from the renal pelvis into the ureter. The following are the most common symptoms (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pain, which varies from a mild and barely noticeable ache to discomfort that is so intense that it requires parenteral analgesics. The pain typically waxes and wanes in severity, and develops in waves or paroxysms that are related to movement of the stone in the ureter and associated ureteral spasm (renal colic). Paroxysms of severe pain usually last 20 to 60 minutes. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gross or microscopic hematuria occurs in the majority of patients presenting with symptomatic nephrolithiasis (70 to 90 percent). Other than visualization of a stone or gravel, this is the single most discriminating predictor of a kidney stone in patients presenting with unilateral flank pain. On the other hand, the absence of hematuria in the setting of acute flank pain does not exclude the presence of nephrolithiasis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other symptoms that are commonly seen include nausea, vomiting, dysuria, and urinary urgency. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nephrolithiasis may lead to persistent renal obstruction, which could cause permanent renal damage if left untreated. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several conditions may mimic renal colic with or without hematuria, including renal cell carcinoma, ectopic pregnancy, aortic aneurysm, and acute intestinal obstruction or appendicitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of nephrolithiasis is initially suspected by the clinical presentation and then confirmed with radiologic imaging. Possible confirmatory radiologic tests include abdominal plain film, intravenous pyelography (IVP), ultrasonography, and most commonly, non-contrasted helical computed tomography (CT) scan (",
"      <a class=\"graphic graphic_table graphicRef65056 \" href=\"UTD.htm?18/51/19260\">",
"       table 2",
"      </a>",
"      ).",
"      <strong>",
"       In most patients, a non-contrasted helical CT scan is the test of choice",
"      </strong>",
"      . It is important to appreciate that ureteral dilatation or stranding without a stone on radiologic examination could represent recent passage of a stone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Non-contrast helical CT scan'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In pregnant women or in patients in whom cholecystitis or a gynecologic process is a prominent consideration, ultrasound is the initial diagnostic test of choice, rather than CT scan. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Recommendations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Ultrasonography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with acute renal colic can be managed conservatively with pain medication and hydration until the stone passes (",
"      <a class=\"graphic graphic_algorithm graphicRef83630 \" href=\"UTD.htm?14/52/15182\">",
"       algorithm 1",
"      </a>",
"      ). Nonsteroidal antiinflammatory drugs (NSAIDs) appear to be at least as effective as opiates. Patients can be managed at home if they are able to take oral medications and fluids. Hospitalization is required for those who cannot tolerate oral intake or who have uncontrollable pain or fever. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Pain control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urgent urologic consultation is warranted in patients with urosepsis, acute kidney failure, anuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unyielding pain, nausea, or vomiting. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Acute therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Urology consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stone size is the major determinant of the likelihood of spontaneous stone passage, although stone location is also important. Most stones &le;5 mm in diameter pass spontaneously. For stones larger than 4 mm in diameter, there is a progressive decrease in the spontaneous passage rate, which is unlikely with stones &ge;10 mm in diameter. Proximal ureteral stones are also less likely to pass spontaneously. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Stone passage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       tamsulosin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      have been shown to increase the likelihood of stone passage, with tamsulosin showing slightly better results. Thus, we initiate treatment with tamsulosin (0.4 mg once daily) for four weeks to facilitate spontaneous stone passage in patients with stones &le;10 mm in diameter. Patients are then re-imaged if spontaneous passage has not definitively occurred. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Facilitating stone passage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with stones larger than 10 mm in diameter, patients with significant discomfort, those with significant obstruction or who have not passed the stone after four to six weeks should be referred to urology for potential intervention. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Facilitating stone passage'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H23\">",
"       'Urology consultation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be instructed to strain their urine for several days and bring in any stone that passes for analysis. This will enable the clinician to better plan preventive therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Straining urine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once the acute stone episode is over and the stone, if retrieved, is sent for analysis, the patient should be evaluated for possible underlying causes of stone disease. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Evaluation and subsequent treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/1\">",
"      Fwu CW, Eggers PW, Kimmel PL, et al. Emergency department visits, use of imaging, and drugs for urolithiasis have increased in the United States. Kidney Int 2013; 83:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/2\">",
"      Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. N Engl J Med 1992; 327:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/3\">",
"      Teichman JM. Clinical practice. Acute renal colic from ureteral calculus. N Engl J Med 2004; 350:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/4\">",
"      Evan AP, Lingeman JE, Coe FL, et al. Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 2003; 111:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/5\">",
"      Kim SC, Coe FL, Tinmouth WW, et al. Stone formation is proportional to papillary surface coverage by Randall's plaque. J Urol 2005; 173:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/6\">",
"      Evan AP, Coe FL, Rittling SR, et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int 2005; 68:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/7\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15:3225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/8\">",
"      Hiatt RA, Ettinger B, Caan B, et al. Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. Am J Epidemiol 1996; 144:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/9\">",
"      Kocvara R, Plasgura P, Petr&iacute;k A, et al. A prospective study of nonmedical prophylaxis after a first kidney stone. BJU Int 1999; 84:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/10\">",
"      Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 2002; 346:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/11\">",
"      Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med 1989; 111:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/12\">",
"      Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol 1997; 8:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/13\">",
"      Lloyd SE, Pearce SH, Fisher SE, et al. A common molecular basis for three inherited kidney stone diseases. Nature 1996; 379:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/14\">",
"      Goodyer P, Saadi I, Ong P, et al. Cystinuria subtype and the risk of nephrolithiasis. Kidney Int 1998; 54:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/15\">",
"      Boll&eacute;e G, Dollinger C, Boutaud L, et al. Phenotype and genotype characterization of adenine phosphoribosyltransferase deficiency. J Am Soc Nephrol 2010; 21:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/16\">",
"      Asplin JR, Coe FL. Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. J Urol 2007; 177:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/17\">",
"      Nelson WK, Houghton SG, Milliner DS, et al. Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/18\">",
"      Duffey BG, Pedro RN, Makhlouf A, et al. Roux-en-Y gastric bypass is associated with early increased risk factors for development of calcium oxalate nephrolithiasis. J Am Coll Surg 2008; 206:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/19\">",
"      Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997; 127:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/20\">",
"      Sasson JP, Dratch PL, Shortsleeve MJ. Renal US findings in sulfadiazine-induced crystalluria. Radiology 1992; 185:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/21\">",
"      Carr MC, Prien EL Jr, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/22\">",
"      Avci Z, Koktener A, Uras N, et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child 2004; 89:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/23\">",
"      Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hypertension: population based study of an independent clinical association. BMJ 1990; 300:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/24\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int 2005; 68:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/25\">",
"      Gillen DL, Coe FL, Worcester EM. Nephrolithiasis and increased blood pressure among females with high body mass index. Am J Kidney Dis 2005; 46:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/26\">",
"      Gillen DL, Worcester EM, Coe FL. Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 2005; 67:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/27\">",
"      Rodgers AL, Greyling KG, Noakes TD. Crystalluria in marathon runners. III. Stone-forming subjects. Urol Res 1991; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/28\">",
"      Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/29\">",
"      Pearle MS, Calhoun EA, Curhan GC, Urologic Diseases of America Project. Urologic diseases in America project: urolithiasis. J Urol 2005; 173:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/30\">",
"      Scales CD Jr, Curtis LH, Norris RD, et al. Changing gender prevalence of stone disease. J Urol 2007; 177:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/31\">",
"      Daudon M, Traxer O, Conort P, et al. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006; 17:2026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/32\">",
"      Ekeruo WO, Tan YH, Young MD, et al. Metabolic risk factors and the impact of medical therapy on the management of nephrolithiasis in obese patients. J Urol 2004; 172:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/33\">",
"      Abate N, Chandalia M, Cabo-Chan AV Jr, et al. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int 2004; 65:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/34\">",
"      Cameron MA, Maalouf NM, Adams-Huet B, et al. Urine composition in type 2 diabetes: predisposition to uric acid nephrolithiasis. J Am Soc Nephrol 2006; 17:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/35\">",
"      Taylor EN, Curhan GC. Body size and 24-hour urine composition. Am J Kidney Dis 2006; 48:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/36\">",
"      Glowacki LS, Beecroft ML, Cook RJ, et al. The natural history of asymptomatic urolithiasis. J Urol 1992; 147:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/37\">",
"      Elton TJ, Roth CS, Berquist TH, Silverstein MD. A clinical prediction rule for the diagnosis of ureteral calculi in emergency departments. J Gen Intern Med 1993; 8:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/38\">",
"      Bove P, Kaplan D, Dalrymple N, et al. Reexamining the value of hematuria testing in patients with acute flank pain. J Urol 1999; 162:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/39\">",
"      Press SM, Smith AD. Incidence of negative hematuria in patients with acute urinary lithiasis presenting to the emergency room with flank pain. Urology 1995; 45:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/40\">",
"      Kobayashi T, Nishizawa K, Mitsumori K, Ogura K. Impact of date of onset on the absence of hematuria in patients with acute renal colic. J Urol 2003; 170:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/41\">",
"      Teichman JM, Long RD, Hulbert JC. Long-term renal fate and prognosis after staghorn calculus management. J Urol 1995; 153:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/42\">",
"      Sarma DP, Deiparine EM, Weilbaecher TG. Partially calcified renal cell carcinoma mimicking renal calculus. J La State Med Soc 1990; 142:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/43\">",
"      Jones EE. Ectopic pregnancy: common and some uncommon misdiagnoses. Obstet Gynecol Clin North Am 1991; 18:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/44\">",
"      Jones WA, Cooper TP, Kiviat MD. Munchausen syndrome presenting as urolithiasis. West J Med 1978; 128:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/45\">",
"      Pfister SA, Deckart A, Laschke S, et al. Unenhanced helical computed tomography vs intravenous urography in patients with acute flank pain: accuracy and economic impact in a randomized prospective trial. Eur Radiol 2003; 13:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/46\">",
"      Smith RC, Verga M, McCarthy S, Rosenfield AT. Diagnosis of acute flank pain: value of unenhanced helical CT. AJR Am J Roentgenol 1996; 166:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/47\">",
"      Ulahannan D, Blakeley CJ, Jeyadevan N, Hashemi K. Benefits of CT urography in patients presenting to the emergency department with suspected ureteric colic. Emerg Med J 2008; 25:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/48\">",
"      Dalrymple NC, Verga M, Anderson KR, et al. The value of unenhanced helical computerized tomography in the management of acute flank pain. J Urol 1998; 159:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/49\">",
"      Sheafor DH, Hertzberg BS, Freed KS, et al. Nonenhanced helical CT and US in the emergency evaluation of patients with renal colic: prospective comparison. Radiology 2000; 217:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/50\">",
"      Ha M, MacDonald RD. Impact of CT scan in patients with first episode of suspected nephrolithiasis. J Emerg Med 2004; 27:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/51\">",
"      Smith RC, Rosenfield AT, Choe KA, et al. Acute flank pain: comparison of non-contrast-enhanced CT and intravenous urography. Radiology 1995; 194:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/52\">",
"      Worster A, Preyra I, Weaver B, Haines T. The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. Ann Emerg Med 2002; 40:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/53\">",
"      Schwartz BF, Schenkman N, Armenakas NA, Stoller ML. Imaging characteristics of indinavir calculi. J Urol 1999; 161:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/54\">",
"      Varanelli MJ, Coll DM, Levine JA, et al. Relationship between duration of pain and secondary signs of obstruction of the urinary tract on unenhanced helical CT. AJR Am J Roentgenol 2001; 177:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/55\">",
"      Colistro R, Torreggiani WC, Lyburn ID, et al. Unenhanced helical CT in the investigation of acute flank pain. Clin Radiol 2002; 57:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/56\">",
"      Heneghan JP, Dalrymple NC, Verga M, et al. Soft-tissue \"rim\" sign in the diagnosis of ureteral calculi with use of unenhanced helical CT. Radiology 1997; 202:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/57\">",
"      Smith RC, Verga M, Dalrymple N, et al. Acute ureteral obstruction: value of secondary signs of helical unenhanced CT. AJR Am J Roentgenol 1996; 167:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/58\">",
"      Zilberman DE, Tsivian M, Lipkin ME, et al. Low dose computerized tomography for detection of urolithiasis--its effectiveness in the setting of the urology clinic. J Urol 2011; 185:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/59\">",
"      Jellison FC, Smith JC, Heldt JP, et al. Effect of low dose radiation computerized tomography protocols on distal ureteral calculus detection. J Urol 2009; 182:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/60\">",
"      Williams JC Jr, Paterson RF, Kopecky KK, et al. High resolution detection of internal structure of renal calculi by helical computerized tomography. J Urol 2002; 167:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/61\">",
"      Batchelar DL, Chun SS, Wollin TA, et al. Predicting urinary stone composition using X-ray coherent scatter: a novel technique with potential clinical applications. J Urol 2002; 168:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/62\">",
"      Oehlschl&auml;ger S, Hakenberg OW, Froehner M, et al. Evaluation of chemical composition of urinary calculi by conventional radiography. J Endourol 2003; 17:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/63\">",
"      Zilberman DE, Ferrandino MN, Preminger GM, et al. In vivo determination of urinary stone composition using dual energy computerized tomography with advanced post-acquisition processing. J Urol 2010; 184:2354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/64\">",
"      Matlaga BR, Kawamoto S, Fishman E. Dual source computed tomography: a novel technique to determine stone composition. Urology 2008; 72:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/65\">",
"      Boll DT, Patil NA, Paulson EK, et al. Renal stone assessment with dual-energy multidetector CT and advanced postprocessing techniques: improved characterization of renal stone composition--pilot study. Radiology 2009; 250:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/66\">",
"      Ferrandino MN, Pierre SA, Simmons WN, et al. Dual-energy computed tomography with advanced postimage acquisition data processing: improved determination of urinary stone composition. J Endourol 2010; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/67\">",
"      Sinclair D, Wilson S, Toi A, Greenspan L. The evaluation of suspected renal colic: ultrasound scan versus excretory urography. Ann Emerg Med 1989; 18:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/68\">",
"      Catalano O, Nunziata A, Altei F, Siani A. Suspected ureteral colic: primary helical CT versus selective helical CT after unenhanced radiography and sonography. AJR Am J Roentgenol 2002; 178:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/69\">",
"      Portis AJ, Sundaram CP. Diagnosis and initial management of kidney stones. Am Fam Physician 2001; 63:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/70\">",
"      Springhart WP, Marguet CG, Sur RL, et al. Forced versus minimal intravenous hydration in the management of acute renal colic: a randomized trial. J Endourol 2006; 20:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/71\">",
"      Johnson CM, Wilson DM, O'Fallon WM, et al. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int 1979; 16:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/72\">",
"      Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol 1999; 162:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/73\">",
"      Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol 2002; 178:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/74\">",
"      Parekattil SJ, Kumar U, Hegarty NJ, et al. External validation of outcome prediction model for ureteral/renal calculi. J Urol 2006; 175:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/75\">",
"      Cole RS, Fry CH, Shuttleworth KE. The action of the prostaglandins on isolated human ureteric smooth muscle. Br J Urol 1988; 61:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/76\">",
"      Cordell WH, Wright SW, Wolfson AB, et al. Comparison of intravenous ketorolac, meperidine, and both (balanced analgesia) for renal colic. Ann Emerg Med 1996; 28:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/77\">",
"      Cordell WH, Larson TA, Lingeman JE, et al. Indomethacin suppositories versus intravenously titrated morphine for the treatment of ureteral colic. Ann Emerg Med 1994; 23:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/78\">",
"      Ud&eacute;n P, Rentzhog L, Berger T. A comparative study on the analgesic effects of indomethacin and hydromorphinechloride-atropine in acute, ureteral-stone pain. Acta Chir Scand 1983; 149:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/79\">",
"      Holdgate A, Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ 2004; 328:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/80\">",
"      Safdar B, Degutis LC, Landry K, et al. Intravenous morphine plus ketorolac is superior to either drug alone for treatment of acute renal colic. Ann Emerg Med 2006; 48:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/81\">",
"      Preminger GM. Editorial comment. The value of intensive medical management of distal ureteral calculi in an effort to facilitate spontaneous stone passage. Urology 2000; 56:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/82\">",
"      Porpiglia F, Destefanis P, Fiori C, Fontana D. Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. Urology 2000; 56:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/83\">",
"      Dellabella M, Milanese G, Muzzonigro G. Efficacy of tamsulosin in the medical management of juxtavesical ureteral stones. J Urol 2003; 170:2202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/84\">",
"      Saita A, Bonaccorsi A, Marchese F, et al. Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones. Urol Int 2004; 72 Suppl 1:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/85\">",
"      Dellabella M, Milanese G, Muzzonigro G. Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. Urology 2005; 66:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/86\">",
"      Dellabella M, Milanese G, Muzzonigro G. Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. J Urol 2005; 174:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/87\">",
"      Porpiglia F, Ghignone G, Fiori C, et al. Nifedipine versus tamsulosin for the management of lower ureteral stones. J Urol 2004; 172:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/88\">",
"      Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet 2006; 368:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/89\">",
"      Yilmaz E, Batislam E, Basar MM, et al. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol 2005; 173:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/90\">",
"      Vicentini FC, Mazzucchi E, Brito AH, et al. Adjuvant tamsulosin or nifedipine after extracorporeal shock wave lithotripsy for renal stones: a double blind, randomized, placebo-controlled trial. Urology 2011; 78:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/91\">",
"      Parsons JK, Hergan LA, Sakamoto K, Lakin C. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol 2007; 177:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/92\">",
"      Agrawal M, Gupta M, Gupta A, et al. Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. Urology 2009; 73:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/93\">",
"      Preminger GM, Tiselius HG, Assimos DG, et al. 2007 guideline for the management of ureteral calculi. J Urol 2007; 178:2418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/50/20266/abstract/94\">",
"      Parmar MS. Kidney stones. BMJ 2004; 328:1420.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7366 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20266=[""].join("\n");
var outline_f19_50_20266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2698242\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Non-contrast helical CT scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23999874\">",
"      - Reducing radiation dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H725865\">",
"      - Determination of stone composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Abdominal plain film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Intravenous pyelogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ACUTE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Straining urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pain control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - NSAIDs and opioids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stone passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Facilitating stone passage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      UROLOGY CONSULTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      EVALUATION AND SUBSEQUENT TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2698242\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7366\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7366|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?14/52/15182\" title=\"algorithm 1\">",
"      Management of acute symptomatic nephrolithiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7366|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/21/10577\" title=\"diagnostic image 1A\">",
"      CT scan showing ureteral stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/47/21233\" title=\"diagnostic image 1B\">",
"      CT scan showing large renal pelvic stone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/54/16226\" title=\"diagnostic image 2\">",
"      Medullary sponge kidney CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/7/43123\" title=\"diagnostic image 3\">",
"      KUB showing staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/17/17694\" title=\"diagnostic image 4\">",
"      Intravenous pyelogram showing ureteral stone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7366|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/10/2208\" title=\"picture 1\">",
"      Cystine crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35439\" title=\"picture 2\">",
"      Struvite crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7366|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/35/1596\" title=\"table 1\">",
"      Risk factors for calcium stones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/51/19260\" title=\"table 2\">",
"      Radiology for urolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=related_link\">",
"      Dent's disease (X-linked recessive nephrolithiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/22/29033?source=related_link\">",
"      Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40231?source=related_link\">",
"      Management of struvite or staghorn calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27079?source=related_link\">",
"      Management of ureteral calculi",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38340?source=related_link\">",
"      Nephrolithiasis during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40802?source=related_link\">",
"      Pathogenesis and clinical manifestations of struvite stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/53/28499?source=related_link\">",
"      Patient information: Kidney stones in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/56/43905?source=related_link\">",
"      Patient information: Kidney stones in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/10/27812?source=related_link\">",
"      Renal complications of extracorporeal shock wave lithotripsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/58/39847?source=related_link\">",
"      The first kidney stone and asymptomatic nephrolithiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_50_20267="ST elevation patterns Brugada";
var content_f19_50_20267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patterns of ST abnormalities in leads V1 to V3 in Brugada syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        J wave amplitude",
"       </td>",
"       <td>",
"        &ge;2 mm",
"       </td>",
"       <td>",
"        &ge;2 mm",
"       </td>",
"       <td>",
"        &ge;2 mm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        T wave",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Positive or biphasic",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST-T configuration",
"       </td>",
"       <td>",
"        Coved type",
"       </td>",
"       <td>",
"        Saddle back",
"       </td>",
"       <td>",
"        Saddle back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ST segment (terminal portion)",
"       </td>",
"       <td>",
"        Gradually descending",
"       </td>",
"       <td>",
"        Elevated &ge;1 mm",
"       </td>",
"       <td>",
"        Elevated &lt;1 mm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002; 23:1648. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20267=[""].join("\n");
var outline_f19_50_20267=null;
var title_f19_50_20268="T3 resin test TBG deficiency";
var content_f19_50_20268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T3-resin test in TBG deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 182px; height: 216px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiolabeled T3 (*T3) cannot bind to diminished or absent TBG; as a result, the amount left over to bind to the resin is higher than normal. The serum total T4 is low; the T3-resin uptake and THBR are high, and the serum free T4 index is normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20268=[""].join("\n");
var outline_f19_50_20268=null;
var title_f19_50_20269="features of ectopic pregnancy";
var content_f19_50_20269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80277&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Significance of features associated with ectopic pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Features",
"      </td>",
"      <td class=\"subtitle1\">",
"       SN (percent)",
"      </td>",
"      <td class=\"subtitle1\">",
"       SP (percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Clinical features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Estimated gestational age &lt;70 days",
"      </td>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       27",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Vaginal bleeding",
"      </td>",
"      <td>",
"       69",
"      </td>",
"      <td>",
"       26",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Abdominal pain",
"      </td>",
"      <td>",
"       97",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Abdominal tenderness",
"      </td>",
"      <td>",
"       85",
"      </td>",
"      <td>",
"       50",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Peritoneal signs",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       95",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Cervical motion tenderness",
"      </td>",
"      <td>",
"       33",
"      </td>",
"      <td>",
"       91",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adnexal tenderness",
"      </td>",
"      <td>",
"       69",
"      </td>",
"      <td>",
"       62",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Adnexal mass",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       Transvaginal ultrasound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       No intrauterine gestational sac",
"      </td>",
"      <td>",
"       100",
"      </td>",
"      <td>",
"       89",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       Adnexal mass",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Separate from ovary",
"      </td>",
"      <td class=\"sublist_other\">",
"       93",
"      </td>",
"      <td class=\"sublist_other\">",
"       99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Cardiac activity",
"      </td>",
"      <td class=\"sublist_other\">",
"       20",
"      </td>",
"      <td class=\"sublist_other\">",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Yolk sac or embryo",
"      </td>",
"      <td class=\"sublist_other\">",
"       37",
"      </td>",
"      <td class=\"sublist_other\">",
"       100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Tubal ring/yolk sac or embryo",
"      </td>",
"      <td class=\"sublist_other\">",
"       65",
"      </td>",
"      <td class=\"sublist_other\">",
"       99",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       Fluid in pouch of Douglas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Any",
"      </td>",
"      <td class=\"sublist_other\">",
"       63",
"      </td>",
"      <td class=\"sublist_other\">",
"       69",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Echogenic",
"      </td>",
"      <td class=\"sublist_other\">",
"       56",
"      </td>",
"      <td class=\"sublist_other\">",
"       96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Color-flow Doppler",
"      </td>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       98",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"3\">",
"       &beta;-hCG combined with transvaginal ultrasound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       Empty uterus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &ge;1000 mIU/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       43-96",
"      </td>",
"      <td class=\"sublist_other\">",
"       86-100",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &ge;1500 mIU/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       40-99",
"      </td>",
"      <td class=\"sublist_other\">",
"       84-96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &ge;2000 mIU/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       38-48",
"      </td>",
"      <td class=\"sublist_other\">",
"       80-98",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\" colspan=\"3\">",
"       Adnexal mass*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &ge;1000 mIU/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       73",
"      </td>",
"      <td class=\"sublist_other\">",
"       85",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &ge;1500 mIU/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       46-64",
"      </td>",
"      <td class=\"sublist_other\">",
"       92-96",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       &ge;2000 mIU/mL",
"      </td>",
"      <td class=\"sublist_other\">",
"       55",
"      </td>",
"      <td class=\"sublist_other\">",
"       96",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sn: sensitivity; Sp: specificity; &beta;-hCG: beta human chorionic gonadotropin.",
"     <br>",
"      * Mass or fluid in cul de sac for &beta;-hCG &ge;1500 mIU/mL and &ge;2000 mIU/mL.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ramakrishnan, K, Scheid, DC. Ectopic pregnancy: Forget the \"classic presentation\" if you want to catch it sooner: A new algorithm to improve detection. Journal of Family Practice 2006; 55:388.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20269=[""].join("\n");
var outline_f19_50_20269=null;
var title_f19_50_20270="Contents: Food allergy";
var content_f19_50_20270=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Food allergy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Food allergy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/46/40681\">",
"           Allergic and asthmatic reactions to food additives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30534\">",
"           Allergy testing in eosinophilic esophagitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/14/36072\">",
"           Allergy to meats",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/52/11082\">",
"           Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14808\">",
"           Clinical manifestations of food allergy: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/58/7082\">",
"           Dermatophyte (tinea) infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/12/5321\">",
"           Diagnostic evaluation of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/9/33944\">",
"           Egg allergy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13223\">",
"           Egg allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2042\">",
"           Food allergens: Overview of clinical features and cross-reactivity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/39/3705\">",
"           Food allergy in schools and camps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42759\">",
"           Food allergy: Impact on health-related quality of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/12/2250\">",
"           Food protein-induced enterocolitis syndrome (FPIES)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/21/10585\">",
"           Future diagnostic tools for food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44057\">",
"           Future therapies for food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/17/26904\">",
"           History and physical examination in the patient with possible food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/30/20967\">",
"           Influenza vaccination in individuals with egg allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37430\">",
"           Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/48/18185\">",
"           Management of food allergy: Avoidance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29640\">",
"           Milk allergy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/9/40087\">",
"           Milk allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23433\">",
"           Molecular features of food allergens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7993\">",
"           Nutritional issues in food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/59/20409\">",
"           Oral food challenges for diagnosis and management of food allergies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/42/43689\">",
"           Pathogenesis of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5785\">",
"           Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38457\">",
"           Peanut, tree nut, and seed allergy: Clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9654\">",
"           Peanut, tree nut, and seed allergy: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32919\">",
"           Peanut, tree nut, and seed allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/41/20119\">",
"           Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38776\">",
"           Respiratory manifestations of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/61/16346\">",
"           Seafood allergies: Fish and shellfish",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/12/2248\">",
"           Testing and challenge procedures to evaluate allergic and asthmatic reactions to food additives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12746\">",
"           The natural history of childhood food allergy",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-AAFB403400-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f19_50_20270=[""].join("\n");
var outline_f19_50_20270=null;
var title_f19_50_20271="HALO360 sizing balloon";
var content_f19_50_20271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82456&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    HALO360 sizing balloon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sizing catheter for radiofrequency ablation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: B&Acirc;RRX Medical Inc. Copyright &copy; 2011. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_50_20271=[""].join("\n");
var outline_f19_50_20271=null;
